{ "$schema_version": "5.4", "review_mode": "revision", "claim_restatement": { "index_wording": "The gut microbiome operates as an autonomous upstream master regulator of human health across metabolic, oncological, psychiatric and immunological systems.", "entry_form": "conjunction", "gradeable_restatement": "In humans, prespecified changes in gut microbial community composition are primary upstream causes of disease across distant-organ disease classes.", "restatement_required": true, "split_into": [ "SC1", "SC2", "SC3", "SC4", "SC5" ], "parent_claim": null, "scope_qualifiers": [ { "qualifier": "In humans", "determinable_before_outcome": true, "determined_from": "species/population under review", "action": "retained" }, { "qualifier": "prespecified changes in gut microbial community composition", "determinable_before_outcome": true, "determined_from": "baseline/intervention composition measured before outcome", "action": "replaced with measurable antecedent" }, { "qualifier": "across distant-organ disease classes", "determinable_before_outcome": true, "determined_from": "pre-specified organ-system and disease-class definitions", "action": "retained" } ], "index_entry_note": "Two index entries overlap here and the index says to establish which is claimed before scoring. Grading A parsed the entry against 'Gut microbiome as master regulator'; revision B parsed it against 'Microbiome causality in human systemic disease'. The commissioned topic matches the second entry's central claim, but both prescribe scope-matched aggregation and near-identical subclaims, differing mainly over whether recurrent C. difficile is listed separately. The five-subclaim decomposition below is a superset of both prescriptions and is retained." }, "lay_summary": { "paragraphs": [ "The gut is home to a vast community of bacteria and other microbes. The claim graded here is the strong one: that the particular mix of microbes a person carries is a main cause of disease in organs far from the gut - the heart, the liver, the brain, the body's metabolism - rather than something that shifts after a person is already ill, or that simply reflects what they eat, the medicines they take, and how fast food moves through them.", "The evidence does not establish that. It sits on the third rung of a nine-rung scale: the mechanism is plausible and works in simplified systems, but the causal dependency has not been shown in people at the breadth claimed. What is solid is narrower. In mice, adding a single bacterial species, or blocking one bacterial chemical reaction, changes arthritis, liver tumours and movement problems - real causation, in animals. In people, replacing the gut community cures a stubborn gut infection that follows antibiotics, which is causation too, but it is an infection of the gut itself, not of a distant organ. Transplant trials aimed at distant organs - in Parkinson's disease, in liver disease, in metabolic disease - are mixed: some find a benefit, several find none, and where a benefit appears it is usually confined to one measure and fades within months. Every one of those trials treated people who were already ill, so none can show that a microbial change started the disease.", "The missing experiment is specific, and nobody has done it: choose the microbial feature in advance, change it in people before they are ill, and see whether the disease that follows is changed, in more than one organ, while accounting for diet, medication and how fast the gut moves. Until that exists, the honest reading is that gut microbes can modify some illnesses in some settings, not that they govern health across the body. That is a statement about how much work has been done, not an accusation against the people doing it, and not a reason to discount the parts that are established. A formal survey of the field itself reports considerably more confidence than this review does, and that gap is the single most useful thing on this page." ], "grade_restated_faithfully": true, "claims_referenced": [ "C1", "C5", "C14", "C15", "C18", "C19", "C22", "C28", "C34", "C35", "C36", "C37" ], "jargon_glossed": [ "gut microbiome - the community of microbes living in the intestine", "distant-organ disease - illness in an organ other than the gut itself", "faecal microbiota transplantation - transferring a donor's gut community into a recipient", "germ-free mouse - an animal raised with no microbes at all", "Gamma - the third of nine rungs: plausible mechanism with partial system support" ], "no_practical_advice": true, "written_for": "general reader, no field background" }, "hypothesis": { "name": "Gut microbiome as primary systemic causal determinant", "central_claim": "Gut microbial community composition is a primary causal determinant of human systemic health, with defined compositional shifts causing disease in distant organs.", "proposed_mechanism": "Community composition alters microbial metabolites, barrier function, immune signaling, and host exposures through gut-organ axes; host genotype, diet, transit, medication, and established disease can also reshape the community.", "claimed_scope": "universal", "claimed_level": [ "initiation", "maintenance" ], "is_conjunctive": true, "conjunctive_note": "The claim joins association, causal phenotype movement, human generalization, and primacy; no study isolates all clauses." }, "rubric_routing": { "primary_rubric": "04-microbiome-systemic.md", "secondary_rubrics": [], "index_notes_applied": [ "Two overlapping index entries apply - 'Gut microbiome as master regulator' and 'Microbiome causality in human systemic disease'. Both prescribe scope-matched aggregation; the decomposition used is a superset of both.", "Rodent, recurrent human CDI, narrow human treatment, and broad human scopes are scored separately.", "Index adjudication note applied verbatim: recurrent C. difficile 'is a depleted-niche special case and does not generalise to multi-system regulation - do not let SC3 carry SC4'. It is reported, not aggregated.", "Index adjudication note applied: 'the rodent-to-human scope decision does all the work in this entry; state it explicitly rather than assuming it.'", "Transit, medication, and diet are standing confounders; disease signatures must not be their shadow." ], "rubric_fit_note": "Direct fit; no rubric mismatch." }, "subclaim_matrix": { "subclaims": [ { "id": "SC1", "statement": "Human systemic disease cohorts show reproducible disease-associated differences in gut community composition.", "subclaim_type": "existence", "governing_rubric": "04-microbiome-systemic.md", "claimed_scope": "Human disease-associated community differences across systemic conditions; association only.", "scope": "Human observational cohorts across disease classes; causal direction not implied.", "key_evidence_anchor": "Prospective pre-onset cohorts with prespecified features controlling medication, diet, transit, host genotype, and disease state.", "hsef_level": "Β", "confidence": "Moderate", "governing_cap_or_threshold": "Association-only microbiome work caps at Β.", "rationale": "Disease-associated differences occur, but medication, transit, diet, host genotype, and disease physiology can create or reshape them; association does not establish direction." }, { "id": "SC2", "statement": "Defined microbial manipulations can causally move disease-relevant extraintestinal phenotypes in selected rodent models.", "subclaim_type": "necessity / sufficiency", "governing_rubric": "04-microbiome-systemic.md", "claimed_scope": "Selected susceptible mouse models and model-specific arthritis, metabolic, neurobehavioral, autoimmune, and hepatic tumor phenotypes.", "scope": "Rodent recipients only; forced transfers or deliberate colonization; not human biology.", "key_evidence_anchor": "Defined strain or microbial-function perturbation with add-back, removal or rescue logic across independent extraintestinal disease models, in recipients that are not all gnotobiotic.", "hsef_level": "Ζ", "confidence": "Moderate", "governing_cap_or_threshold": "Ζ threshold quoted verbatim: 'Defined consortium or strain-level causal evidence; Rescue logic; Replication across at least two relevant models or cohorts.' All three are met inside the rodent scope by four lines that do not share a failure mode. Η is not met on its own quoted requirement - 'Narrowed mechanism' and 'Strong exclusion of diet, housing, batch, and handling confounds' - the second of which is demonstrably false for this literature (housing reversal; transfer-efficiency variability). Universal cap 5 binds the inference to SC5, not this subclaim.", "rationale": "Four independent perturbation lines move extraintestinal phenotypes in vivo: single-species add-back into a germ-free susceptible host (SFB, arthritis); removal of a resident microbial function plus metabolite add-back in conventionally raised mice (deoxycholic acid, hepatocellular carcinoma), which is neither gnotobiotic nor a transfer; depletion, recolonization and metabolite substitution in an alpha-synuclein model (short-chain fatty acids, motor and microglial phenotypes); and human-donor community transfer into germ-free recipients with cohousing rescue. Different organisms, mediators, organs and modalities, so no single systematic error produces all four. The fourth line is the weakest: transfer of human obesity-donor communities failed to reproduce the phenotype on a low-fat diet, and a gnotobiotic hepatic phenotype reversed with housing sector - both inside the diet- and context-dependence the transfer literature itself reports.", "dissent_recorded": "Revision B scored this Ε, on the ground that 'the models and causal chains differ' so one narrowed mechanism is not replicated. Rejected: 'Narrowed mechanism' is Η's requirement, not Ζ's, and under the framework's independence test differing mechanisms are evidence for independence rather than against it. B also attributed the change to 'the v5.4 specificity and generalization thresholds', which are not rules in v5.4 or in any rubric." }, { "id": "SC3", "statement": "Restoring gut microbial colonization resistance after antibiotics reduces recurrent C. difficile infection in humans.", "subclaim_type": "sufficiency", "governing_rubric": "04-microbiome-systemic.md", "claimed_scope": "Human recurrent CDI after antibiotics in a depleted intestinal niche.", "scope": "Disease-specific human treatment context; local colonization resistance in an antibiotic-depleted intestinal niche. Out of scope for the graded distant-organ claim: reported, never aggregated.", "key_evidence_anchor": "Randomized microbial restoration trials with recurrence endpoints and a defined product.", "hsef_level": "Ε", "confidence": "High", "governing_cap_or_threshold": "Ε met in this defined clinical niche by randomized recurrence reduction; Ζ is not met because product identity is not strain-resolved with rescue logic across relevant cohorts.", "rationale": "Randomized restoration trials - whole-stool infusion and a purified-spore product - establish a strong context-specific causal effect on recurrent CDI. This is the one human context in which microbial necessity is demonstrated, and it is simultaneously the least generalizable: the niche was deliberately emptied by antibiotics and the outcome is an intestinal infection, not disease in a distant organ. Retained and labelled per the index's explicit instruction not to let it carry the primacy subclaim.", "dissent_recorded": "Revision B deleted this subclaim and its two trials from the ledger. Rejected: the index lists it as a subclaim to score separately, and deleting the field's strongest human causal result understates the evidence rather than scoping it." }, { "id": "SC4", "statement": "Microbiota-directed interventions can alter some distant-organ disease-related endpoints in selected human treatment contexts.", "subclaim_type": "sufficiency", "governing_rubric": "04-microbiome-systemic.md", "claimed_scope": "Selected treated human populations with metabolic syndrome/T2D, cirrhosis-related HE, and Parkinson disease.", "scope": "Treatment-stage outcomes in named human contexts; products mostly crude or incompletely defined.", "key_evidence_anchor": "Blinded human interventions with verified engraftment, organ-specific outcomes, and internal negative controls that show where the effect stops.", "hsef_level": "Ε", "confidence": "Moderate", "governing_cap_or_threshold": "Ε threshold quoted verbatim: 'Requires context-specific causal effect with defined limits. A transferable phenotype exists, but microbial identity or generalizability remains incomplete.' Met: positive randomized effects exist and their limits are mapped by internal negative controls, not merely untested. Ζ is not met because whole-stool products do not resolve strain-level identity with rescue logic.", "rationale": "Positive randomized effects exist in Parkinson disease, in metabolic syndrome and on a secondary hepatic-encephalopathy endpoint, and a human genetic instrument supports a causal contribution of a defined microbial function to a metabolic trait. Their boundary is mapped from inside the positive trials: in GUT-PARFECT the off-medication motor score and objective transit separate while twelve prespecified secondary instruments do not and one moves against, with no separation before six months; the lean-donor metabolic benefit is present at six weeks, gone at eighteen, and predicted by baseline composition; a second enema trial reproduces the same fade; engraftment without effect shows the boundary is not engraftment; no incremental benefit over a Mediterranean diet shows it is partly diet; non-superiority to lactulose shows it is partly standard of care. Mapped limits with incomplete microbial identity is Ε by definition.", "dissent_recorded": "Revision B scored this Δ, on the ground that null trials leave the boundary unmapped. Rejected under Step 10 and pitfall 16 - failed generalization is Ε's definition, not a reason to sit at Δ - and because B had removed five of the six trials that map the boundary from its own ledger." }, { "id": "SC5", "statement": "In humans, gut microbial community composition is an autonomous primary upstream cause of disease across multiple distant-organ disease classes.", "subclaim_type": "primacy", "governing_rubric": "04-microbiome-systemic.md", "claimed_scope": "Broad human systemic disease initiation and maintenance across distant-organ classes.", "scope": "Multi-system human primacy; no outcome-defined susceptibility qualifier.", "key_evidence_anchor": "Pre-onset human evidence plus a defined endogenous, genetic-instrument or randomized community perturbation changing incident or progressive disease in at least two distant-organ systems while controlling host, diet, transit, and medication.", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Γ: no qualifying defined endogenous human community shift establishes primary causation across disease classes; forced-transfer evidence cannot carry that inference under cap 5.", "rationale": "Animal perturbation, narrow human interventions, a human genetic instrument for one microbial function, and a human microbial-function withdrawal experiment together provide partial system support across several evidence classes. None of them, singly or together, establishes composition as primary across human distant-organ disease: the genetic instrument covers one function against one trait class in one cohort and is partly confounded with host absorption; the withdrawal experiment's human endpoint is a metabolite, which cap 4 holds at Γ; the clinical trials all begin after diagnosis; and diet, transit and medication are demonstrated determinants of the very composition offered as the cause." } ], "aggregation_rule": "scope-matched", "aggregation_preregistered": true, "aggregation_rationale": "Before scoring, broad human multi-system primacy was designated as the overall target; stronger animal, CDI, and narrow human intervention findings remain separately scoped.", "primary_subclaim_id": "SC5", "aggregation_derivation": "SC5 is Γ and sets the scope-matched overall letter, because the graded claim is asserted at broad human multi-system scope. SC2 is Ζ only inside selected rodent models, SC3 is Ε inside the antibiotic-depleted CDI niche and is out of scope for a distant-organ claim, and SC4 is Ε for selected human treatment contexts. None of the three higher subclaims shares the graded scope, so none of them can raise the letter.", "aggregation_alternatives": { "weakest_link_would_return": "Β", "primary_subclaim_would_return": "Γ", "scope_matched_would_return": "Γ", "note": "Recomputed independently over {SC1 Β, SC2 Ζ, SC3 Ε, SC4 Ε, SC5 Γ}: weakest-link returns Β because association-only SC1 is the floor; primary-subclaim on SC5 and scope-matched both return Γ. Aggregation changes the letter by one rung, and the rule was pre-registered before scoring in both input gradings, so there is no sign of rule-shopping in either." }, "index_rule_deviation": "Scope-matched is used as both overlapping index entries prescribe. The master-regulator entry's four subclaims are retained and a fifth (SC4) is added to separate treatment-stage human effects from broad primacy, which Step 2 permits where the evidence base warrants; the human interventional literature here is large enough to warrant it. Revision B's four-subclaim decomposition, which drops the recurrent-CDI subclaim entirely, is recorded as dissent and not adopted." }, "competing_models": { "models_evaluated": [ { "rank_in_tournament": 1, "model_id": "M1", "is_nominal": false, "name": "Host-, disease-, and exposure-first reciprocal ecosystem", "core_claim": "Host physiology, diet, transit, medication, genotype, and established disease shape community composition, while microbes feed back on selected phenotypes.", "explains_what_nominal_does_not": "Explains disease signatures, variable response and transfer heterogeneity while allowing genuine niche-specific microbial effects.", "strongest_supporting_evidence": [ "[24]–[27]", "[10]", "[19]" ], "strongest_contradictory_evidence": [ "[18]", "[20]–[21]" ], "hsef_level_for_this_model": "Ε", "rationale": "Medication and transit affect measured composition; positive transfers indicate reciprocal context-specific effects, so microbes are not inert." }, { "rank_in_tournament": 2, "model_id": "M2", "is_nominal": false, "name": "Niche-specific microbial causality", "core_claim": "Microbes become causal when host state or a depleted niche makes a microbial function rate-limiting.", "explains_what_nominal_does_not": "Explains strong causal perturbation results without requiring microbial primacy across systems.", "strongest_supporting_evidence": [ "[1]–[7]", "[14]–[15]", "[18]", "[20]–[21]" ], "strongest_contradictory_evidence": [ "[9]–[13]", "[19]", "[22]–[23]" ], "hsef_level_for_this_model": "Ζ", "rationale": "Strong evidence clusters in selected animal models and CDI, with emerging but mixed human treatment effects." }, { "rank_in_tournament": 3, "model_id": "M3", "is_nominal": true, "name": "Gut microbiome as autonomous multi-system master regulator", "core_claim": "Community composition autonomously acts as a primary upstream determinant of human health across distant organs and disease classes.", "explains_what_nominal_does_not": "Unifies gut-organ axes under a common causal community mechanism.", "strongest_supporting_evidence": [ "[1]–[5]", "[14]–[18]", "[20]–[21]" ], "strongest_contradictory_evidence": [ "[9]–[13]", "[19]", "[22]–[27]" ], "hsef_level_for_this_model": "Γ", "rationale": "Plausible mechanisms and partial-system support exist, but human primacy/generalization is not established." }, { "rank_in_tournament": 4, "model_id": "M4", "is_nominal": false, "name": "Diet-substrate control", "core_claim": "Diet is a dominant upstream determinant of microbial function and systemic outcomes.", "explains_what_nominal_does_not": "Explains diet-dependent transfer results and variable metabolic response.", "strongest_supporting_evidence": [ "[2]", "[10]", "[26]" ], "strongest_contradictory_evidence": [ "[1]", "[14]–[15]", "[18]–[21]" ], "hsef_level_for_this_model": "Ε", "rationale": "Diet materially shapes microbial output but cannot fully explain all microbial intervention effects." }, { "rank_in_tournament": 5, "model_id": "M5", "is_nominal": false, "name": "Host-genotype and physiology gating", "core_claim": "Host genotype, immunity, barrier state, and transit determine whether a community feature affects disease.", "explains_what_nominal_does_not": "Explains model-specific penetrance, variable engraftment, and different outcomes across recipients.", "strongest_supporting_evidence": [ "[1]", "[4]", "[6]", "[7]", "[24]–[26]" ], "strongest_contradictory_evidence": [ "[2]", "[14]–[15]", "[18]–[21]" ], "hsef_level_for_this_model": "Ε", "rationale": "Host gating is supported but does not make microbial causality impossible; it challenges a uniform autonomous effect." } ], "tournament_summary": "Shared evidence favors reciprocal host/context gating with niche-specific microbial effects. The nominal master-regulator model ranks third and does not explain heterogeneity without narrowing its scope.", "study_separating_rank1_from_rank2": "No completed study decisively separates broad primacy from host/context-first causation; a replicated pre-onset human defined-community perturbation with organ outcomes is needed.", "nominal_wins_only_by_funding_artifact": false, "level_unchanged_by_tournament": true }, "evidence_inventory": [ { "citation": "Wu HJ et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity. 2010;32:815–827.", "source_pointer": "PMID:20620945", "relates_to_subclaims": [ "SC2" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Defined SFB colonization moved arthritis-related phenotypes in susceptible mice.", "what_it_does_not_show": "Does not show human systemic primacy or generalization across genotypes.", "confounders_present": [ "Susceptible mouse model", " forced colonization", " housing/cage effects" ], "verification": "verified", "verification_note": "Title, identifier, publication record, and result checked in PubMed abstract or publisher record on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Ridaura VK et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013;341:1241214.", "source_pointer": "PMID:24009397", "relates_to_subclaims": [ "SC2" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Human-source communities transferred selected metabolic phenotypes to germ-free mice; effects depended on diet and community interaction.", "what_it_does_not_show": "Does not establish obesity causation in humans or primacy across diseases.", "confounders_present": [ "Germ-free recipient physiology", " diet dependence", " cage/cohousing", " forced transfer" ], "verification": "verified", "verification_note": "Title, identifier, publication record, and result checked in PubMed abstract or publisher record on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Hsiao EY et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell. 2013;155:1451–1463.", "source_pointer": "PMID:24315484", "relates_to_subclaims": [ "SC2" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "A defined microbial intervention modified disease-relevant phenotypes in a selected mouse model.", "what_it_does_not_show": "Does not show primary causation of human neurodevelopmental disease.", "confounders_present": [ "Maternal immune activation model", " intervention after induction", " pooled samples for select metabolite assays" ], "verification": "verified", "verification_note": "Title, identifier, publication record, and result checked in PubMed abstract or publisher record on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Manfredo Vieira S et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans. Science. 2018;359:1156–1161.", "source_pointer": "PMID:29590047", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "A gut pathobiont can promote autoimmune phenotypes in susceptible mice with human tissue observations.", "what_it_does_not_show": "Human tissue does not prove human autoimmune causation.", "confounders_present": [ "Susceptible mouse backgrounds", " antibiotic/vaccine effects", " human observations only" ], "verification": "verified", "verification_note": "Title, identifier, publication record, and result checked in PubMed abstract or publisher record on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Yoshimoto S et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013;499:97–101.", "source_pointer": "PMID:23803760", "relates_to_subclaims": [ "SC2" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Endogenous microbial function contributed to liver tumor signaling in an obese/carcinogen mouse context.", "what_it_does_not_show": "Does not establish human cancer primacy; mechanism is a metabolite in an induced model.", "confounders_present": [ "Chemical carcinogen", " obesity-specific", " broad antibiotic perturbation" ], "verification": "verified", "verification_note": "Title, identifier, publication record, and result checked in PubMed abstract or publisher record on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Bloom SM et al. Commensal Bacteroides species induce colitis in host-genotype-specific fashion in a mouse model of inflammatory bowel disease. Cell Host Microbe. 2011;9:390–403.", "source_pointer": "PMID:21575910", "relates_to_subclaims": [ "SC5" ], "favors_models": [ "M1" ], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Microbial effects can be host-genotype gated; disease enrichment did not predict pathogenicity.", "what_it_does_not_show": "Intestinal mouse disease, not distant-organ or human primacy.", "confounders_present": [ "Specific IBD genotype", " colonization model", " one host-microbial setting" ], "verification": "verified", "verification_note": "Title, identifier, publication record, and result checked in PubMed abstract or publisher record on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Gray SM et al. Mouse adaptation of human IBD microbiota enhances colonization efficiency and alters microbiome aggressiveness depending on recipient inflammation. Microbiome. 2024;12:147.", "source_pointer": "PMID:39113097", "relates_to_subclaims": [ "SC5" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Recipient host environment can shape transferred-community effects.", "what_it_does_not_show": "Does not establish human systemic causation.", "confounders_present": [ "Mouse adaptation", " recipient inflammation", " transfer paradigm" ], "verification": "verified", "verification_note": "Title, identifier, publication record, and result checked in PubMed abstract or publisher record on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Kootte RS et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metabolism. 2017;26:611–619.e6.", "source_pointer": "PMID:28978426", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Crude community transfer had a short-term metabolic effect in a defined population.", "what_it_does_not_show": "Does not show disease onset, durable benefit, specific taxa, or primacy.", "confounders_present": [ "Small selected cohort", " transient response", " baseline microbiota modifies response" ], "verification": "verified", "verification_note": "Title, identifier, publication record, and result checked in PubMed abstract or publisher record on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Yu EW et al. Fecal microbiota transplantation for the improvement of metabolism in obesity: The FMT-TRIM double-blind placebo-controlled pilot trial. PLoS Med. 2020;17(3):e1003051.", "source_pointer": "PMID:32150549", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "Microbiome change did not guarantee metabolic phenotype change.", "what_it_does_not_show": "Small pilot cannot exclude effects in other contexts.", "confounders_present": [ "Small sample", " obesity/insulin-resistance cohort", " limited duration" ], "verification": "verified", "verification_note": "Title, identifier, publication record, and result checked in PubMed abstract or publisher record on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Koopen AM et al. Effect of Fecal Microbiota Transplantation Combined With Mediterranean Diet on Insulin Sensitivity in Subjects With Metabolic Syndrome. Front Microbiol. 2021;12:662159.", "source_pointer": "PMID:34177842", "relates_to_subclaims": [ "SC4", "SC5" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "Diet and baseline context can dominate response; FMT did not add clear benefit.", "what_it_does_not_show": "Does not establish microbiota are irrelevant in other contexts.", "confounders_present": [ "Small cohort", " diet intervention", " crude donor FMT" ], "verification": "verified", "verification_note": "Title, identifier, publication record, and result checked in PubMed abstract or publisher record on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Wu Z et al. Fecal microbiota transplantation reverses insulin resistance in type 2 diabetes: A randomized, controlled, prospective study. Front Cell Infect Microbiol. 2023;12:1089991.", "source_pointer": "PMID:36704100", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Small human intervention gives a short-term metabolic signal.", "what_it_does_not_show": "Does not establish onset, durable disease benefit, or taxa as primary drivers.", "confounders_present": [ "Very small arms", " 4-week follow-up", " no sham placebo", " procedure and medication effects" ], "verification": "verified", "verification_note": "Title, identifier, publication record, and result checked in PubMed abstract or publisher record on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Piwchan S et al. Fecal Microbiota Transplantation by Rectal Enema Improves Short-Term Insulin Resistance in Metabolic Syndrome: A Pilot Randomized Controlled Trial. J Obes Metab Syndr. 2025;34(4):434–445.", "source_pointer": "PMID:40916606", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Small sham-controlled transfer trial reported short-term insulin-resistance improvement.", "what_it_does_not_show": "Does not show persistent disease modification or strain-level cause.", "confounders_present": [ "18 participants", " pilot", " effect not sustained at 12 weeks" ], "verification": "verified", "verification_note": "Title, identifier, publication record, and result checked in PubMed abstract or publisher record on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Fecal microbiota transplantation in patients with metabolic syndrome and obesity: randomized controlled trial. 2023. PMID 37469721.", "source_pointer": "PMID:37469721", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "Community composition can change without measured systemic outcomes changing.", "what_it_does_not_show": "Does not rule out another intervention or phenotype.", "confounders_present": [ "Small single-blind trial", " microbiota-change primary endpoint" ], "verification": "verified", "verification_note": "Title, identifier, publication record, and result checked in PubMed abstract or publisher record on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "van Nood E et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407–415.", "source_pointer": "PMID:23323867", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Microbiota restoration causally restores colonization resistance in a depleted local niche.", "what_it_does_not_show": "Does not show distant-organ disease causation or generalize beyond CDI.", "confounders_present": [ "Post-antibiotic depleted niche", " early small RCT", " crude FMT" ], "verification": "verified", "verification_note": "Title, identifier, publication record, and result checked in PubMed abstract or publisher record on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Feuerstadt P et al. SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med. 2022;386(3):220–229.", "source_pointer": "PMID:35045228", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Purified oral spores reduced recurrence after antibiotic treatment.", "what_it_does_not_show": "Does not establish broad primary systemic causation.", "confounders_present": [ "Post-antibiotic CDI", " treatment not initiation", " product, not strain-by-strain attribution" ], "verification": "verified", "verification_note": "Title, identifier, publication record, and result checked in PubMed abstract or publisher record on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Bajaj JS et al. Microbiota transplant for hepatic encephalopathy in cirrhosis: The THEMATIC trial. J Hepatol. 2025;83:81–91.", "source_pointer": "PMID:39800192", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Treatment signal for recurrent HE in a narrow adjunctive setting.", "what_it_does_not_show": "Secondary/post hoc effects do not show microbiota initiated liver disease or is its primary cause.", "confounders_present": [ "Small phase II", " safety primary", " advanced cirrhosis", " secondary/post hoc clinical outcomes" ], "verification": "verified", "verification_note": "Title, identifier, publication record, and result checked in PubMed abstract or publisher record on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Agarwal A et al. Impact of two-session fecal microbiota transplantation on minimal hepatic encephalopathy in cirrhosis. World J Hepatol. 2026;18(4):116153.", "source_pointer": "DOI:10.4254/wjh.v18.i4.116153", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "FMT was not superior to lactulose for minimal HE resolution.", "what_it_does_not_show": "An active-comparator null does not show microbiota are irrelevant.", "confounders_present": [ "Open-label single center", " active comparator", " tertiary cirrhosis" ], "verification": "verified", "verification_note": "Title, identifier, publication record, and result checked in PubMed abstract or publisher record on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "GUT-PARFECT trial. Donor vs autologous FMT in mild-moderate Parkinson disease. EClinicalMedicine. 2024;71:102563.", "source_pointer": "NCT03808389", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Small controlled trial reported a durable motor-scale signal in early Parkinson disease.", "what_it_does_not_show": "Does not show disease prevention, defined microbial identity, or primacy.", "confounders_present": [ "Single center", " small sample", " one positive scale", " donor FMT not defined strains" ], "verification": "verified", "verification_note": "Title, identifier, publication record, and result checked in PubMed abstract or publisher record on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Scheperjans F et al. Fecal Microbiota Transplantation for Treatment of Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2024;81(9):925–938.", "source_pointer": "NCT04854291", "relates_to_subclaims": [ "SC4", "SC5" ], "favors_models": [ "M1" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "Larger multicenter trial did not confirm primary benefit despite microbiota changes.", "what_it_does_not_show": "One null trial does not exclude subgroups or another intervention.", "confounders_present": [ "Modest sample", " donor heterogeneity", " bowel prep/placebo", " follow-up" ], "verification": "verified", "verification_note": "Title, identifier, publication record, and result checked in PubMed abstract or publisher record on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Wang J et al. Colonoscopic fecal microbiota transplantation for Mild-to-Moderate Parkinson's Disease: A randomized controlled trial. Brain Behav Immun. 2025;130:106086.", "source_pointer": "PMID:40848995", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Very small trial provides a short-term Parkinson symptom signal.", "what_it_does_not_show": "Does not establish disease initiation or long-term disease modification.", "confounders_present": [ "30 participants", " single center", " 12-week follow-up", " multiple scales" ], "verification": "verified", "verification_note": "Title, identifier, publication record, and result checked in PubMed abstract or publisher record on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Zhang R et al. Gut microbiota modulation via repeated donor fecal transplantation improves motor and gastrointestinal symptoms in drug-naïve Parkinson's disease: a randomized phase 2 trial. Signal Transduct Target Ther. 2026;11(1):94.", "source_pointer": "ChiCTR2200064151", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Phase II trial supports a possible human microbiota contribution to motor symptoms in one early disease context.", "what_it_does_not_show": "Does not show a prespecified community shift caused onset or is primary across diseases.", "confounders_present": [ "Phase II", " single setting", " short neurodegeneration follow-up", " crude transfer" ], "verification": "verified", "verification_note": "Title, identifier, publication record, and result checked in PubMed abstract or publisher record on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Figura M et al. Safety and Efficacy of Fecal Microbiota Transplantation in Alleviating Symptoms of Parkinson's Disease: A Randomized, Placebo-Controlled, Double-Blinded Study. Ann Neurol. 2026;100(1):10–21.", "source_pointer": "NCT05204641", "relates_to_subclaims": [ "SC4", "SC5" ], "favors_models": [ "M1" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "2026 trial did not confirm a one-year motor benefit.", "what_it_does_not_show": "Does not exclude nonmotor or context-specific effects.", "confounders_present": [ "Moderate sample", " single FMT", " autologous placebo", " multiple secondary outcomes" ], "verification": "verified", "verification_note": "Title, identifier, publication record, and result checked in PubMed abstract or publisher record on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Fretheim H et al. ReSScue phase II trial of fecal microbiota transplantation in systemic sclerosis. 2025. PMID 39900089.", "source_pointer": "NCT04300426", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M1" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "Randomized systemic-sclerosis cohort did not show primary symptom benefit.", "what_it_does_not_show": "Local GI endpoint does not directly test distant-organ causation.", "confounders_present": [ "Systemic sclerosis with GI involvement", " cultured community", " symptom endpoint" ], "verification": "verified", "verification_note": "Title, identifier, publication record, and result checked in PubMed abstract or publisher record on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Forslund K et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015;528(7581):262–266.", "source_pointer": "PMID:26633628", "relates_to_subclaims": [ "SC1", "SC5" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Medication can cause or alter a disease-associated microbial signature.", "what_it_does_not_show": "Does not establish microbial primacy or causal direction.", "confounders_present": [ "Medication confounding", " cross-sectional sampling" ], "verification": "verified", "verification_note": "Title, identifier, publication record, and result checked in PubMed abstract or publisher record on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Vandeputte D et al. Stool consistency associated with gut microbiota richness and composition. Gut. 2016;65:57–62.", "source_pointer": "PMID:26069274", "relates_to_subclaims": [ "SC1", "SC5" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Transit-related physiology is associated with microbiome composition independent of diagnosed disease.", "what_it_does_not_show": "Does not prove transit explains every disease signature or exclude feedback.", "confounders_present": [ "Imperfect transit proxy", " observational", " restricted sample" ], "verification": "verified", "verification_note": "Title, identifier, publication record, and result checked in PubMed abstract or publisher record on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Falony G et al. Population-level analysis of gut microbiome variation. Science. 2016;352:560–564.", "source_pointer": "PMID:27126039", "relates_to_subclaims": [ "SC1", "SC5" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Host, medication, and environment influence microbiome composition and confound disease association.", "what_it_does_not_show": "Does not establish direction for any one disease.", "confounders_present": [ "Observational", " residual confounding", " covariate error" ], "verification": "verified", "verification_note": "Title, identifier, publication record, and result checked in PubMed abstract or publisher record on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Wu H et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017;23(7):850–858.", "source_pointer": "PMID:28530702", "relates_to_subclaims": [ "SC1", "SC2", "SC5" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Drug can alter composition and community may mediate part of drug effect in mice.", "what_it_does_not_show": "Does not show baseline microbiota is upstream of human T2D; metformin is a directionality confound.", "confounders_present": [ "Drug direct host effects", " forced stool transfer", " treatment-induced exposure" ], "verification": "verified", "verification_note": "Title, identifier, publication record, and result checked in PubMed abstract or publisher record on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Sampson TR et al. Cell. 2016;167(6):1469-1480.e12.", "source_pointer": "PMID:27912057", "relates_to_subclaims": [ "SC2" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Microbiota depletion reduced, and recolonization or short-chain fatty acid administration restored, motor deficits and microglial activation in an alpha-synuclein model.", "what_it_does_not_show": "Does not show that human gut communities initiate Parkinson disease.", "confounders_present": [ "Transgenic overexpression model", " germ-free rearing", " housing and diet" ], "verification": "verified", "verification_note": "Record and result checked against PubMed or the publisher on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Neyrinck AM et al. Sci Rep. 2025;15(1):15455.", "source_pointer": "PMID:40316655", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [ "M1", "M4", "M5" ], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "null", "what_it_shows": "Human obesity-donor communities shifted recipient taxa and caecal metabolites without reproducing the metabolic or behavioural phenotype.", "what_it_does_not_show": "Does not show that donor-community transfer never works; the recipients were on a low-fat diet, which is the condition under which the twin-transfer study also reported no effect.", "confounders_present": [ "Antibiotic pretreatment rather than germ-free", " low-fat chow diet", " donor selection" ], "verification": "verified", "verification_note": "Record and result checked against PubMed or the publisher on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Daoust L et al. Gut. 2023;72(5):896-905.", "source_pointer": "PMID:36881441", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [ "M1", "M5" ], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "The hepatic phenotype following one gnotobiotic colonization reversed direction with the recipients' housing sector.", "what_it_does_not_show": "Does not identify which housing variable is responsible.", "confounders_present": [ "Housing sector", " facility microbiota", " diet" ], "verification": "verified", "verification_note": "Record and result checked against PubMed or the publisher on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Vrieze A et al. Gastroenterology. 2012;143(4):913-916.e7.", "source_pointer": "PMID:22728514", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Lean-donor microbiota infusion improved insulin sensitivity at six weeks in men with metabolic syndrome.", "what_it_does_not_show": "Small, short, undefined product, no distant-organ clinical endpoint.", "confounders_present": [ "Small n", " bowel preparation", " undefined donor community" ], "verification": "verified", "verification_note": "Record and result checked against PubMed or the publisher on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "David LA et al. Nature. 2014;505(7484):559-563.", "source_pointer": "PMID:24336217", "relates_to_subclaims": [ "SC1", "SC5" ], "favors_models": [ "M1", "M4" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "contradicts", "what_it_shows": "Short-term dietary switches rapidly and reproducibly reconfigured the human gut community and its gene expression.", "what_it_does_not_show": "Does not show that diet-driven community change causes or prevents disease.", "confounders_present": [ "Short duration", " small n", " extreme diets" ], "verification": "verified", "verification_note": "Record and result checked against PubMed or the publisher on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Roager HM et al. Nat Microbiol. 2016;1(9):16093.", "source_pointer": "PMID:27562254", "relates_to_subclaims": [ "SC1", "SC5" ], "favors_models": [ "M1" ], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": true, "direction": "contradicts", "what_it_shows": "Colonic transit time tracks community composition, richness and the fermentation-to-catabolism balance.", "what_it_does_not_show": "Observational; does not establish the direction between transit and community.", "confounders_present": [ "Cross-sectional", " diet", " self-selection" ], "verification": "verified", "verification_note": "Record and result checked against PubMed or the publisher on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Prosty C et al. eGastroenterology. 2024;2(3):e100086.", "source_pointer": "DOI:10.1136/egastro-2024-100086", "relates_to_subclaims": [ "SC4", "SC5" ], "favors_models": [ "M2" ], "evidence_class": "Weak", "system": "review", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "A field review placing established human causal evidence in recurrent CDI, ulcerative colitis and immunotherapy response, and reporting that obesity trials have not delivered.", "what_it_does_not_show": "Not primary evidence; carries no experimental number here.", "confounders_present": [ "Narrative review", " selection of included trials" ], "verification": "verified", "verification_note": "Record and result checked against PubMed or the publisher on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "B" }, { "citation": "Metwaly A et al. Nat Rev Gastroenterol Hepatol. 2025;22(5):343-356.", "source_pointer": "PMID:40033063", "relates_to_subclaims": [ "SC5" ], "favors_models": [ "M1" ], "evidence_class": "Weak", "system": "consensus statement", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "The field's own Delphi instrument, used here only to fix the implied level for Divergence.", "what_it_does_not_show": "Expert opinion about evidence, not evidence; carries no experimental number here.", "confounders_present": [ "Respondent selection", " opinion rather than data" ], "verification": "verified", "verification_note": "Record and result checked against PubMed or the publisher on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "B" }, { "citation": "Sanna S et al. Nat Genet. 2019;51(4):600-605.", "source_pointer": "PMID:30778224", "relates_to_subclaims": [ "SC4", "SC5" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Strong", "system": "natural experiment", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "A human genetic instrument: host-genetics-driven butyrate production tracks improved insulin response, and abnormal propionate handling is causally related to type 2 diabetes risk.", "what_it_does_not_show": "Instruments a microbial function, not community composition; one trait class, one cohort, partly confounded with host absorption; says nothing about primacy across disease classes.", "confounders_present": [ "Weak-instrument risk", " host pleiotropy (LCT, secretor status)", " single cohort" ], "verification": "verified", "verification_note": "Record and result checked against PubMed or the publisher on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Koeth RA et al. Nat Med. 2013;19(5):576-585.", "source_pointer": "PMID:23563705", "relates_to_subclaims": [ "SC5" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Human antibiotic suppression abolished carnitine-derived TMAO production and it returned on recovery; microbiota suppression abolished carnitine-driven atherosclerosis in mice.", "what_it_does_not_show": "The human endpoint is a circulating metabolite and the human clinical endpoint is observational; cap 4 and cap 2 bind respectively.", "confounders_present": [ "Antibiotic pleiotropy", " diet", " observational clinical endpoint" ], "verification": "verified", "verification_note": "Record and result checked against PubMed or the publisher on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Bajaj JS et al. Hepatology. 2017;66(6):1727-1738.", "source_pointer": "PMID:28586116", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M2", "M3" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Randomized transplant from a rationally selected donor reduced further hepatic-encephalopathy episodes and serious adverse events versus standard of care.", "what_it_does_not_show": "Open-label, twenty participants, and the active arm received antibiotic pretreatment, so the microbial contribution is not isolated.", "confounders_present": [ "Open label", " antibiotic pretreatment", " small n", " single donor" ], "verification": "verified", "verification_note": "Record and result checked against PubMed or the publisher on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Davar D et al. Science. 2021;371(6529):595-602.", "source_pointer": "PMID:33542131", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M2" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Responder-derived transplant with anti-PD-1 produced clinical benefit in a subset of patients whose melanoma had progressed on anti-PD-1.", "what_it_does_not_show": "Single-arm: no randomized comparator, so response cannot be separated from natural history or from continued anti-PD-1.", "confounders_present": [ "No control arm", " small n", " donor selection", " concomitant therapy" ], "verification": "verified", "verification_note": "Record and result checked against PubMed or the publisher on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" } ], "verification_summary": { "load_bearing_claims_checked": 39, "verified": 38, "unverified": 1, "contradicted": 0, "note": "Every registered claim of both input gradings, plus the twelve added in this edition, was checked against the source record on 2026-09-27; numbers were compared digit for digit and direction was checked separately from magnitude. Full text was read where a figure or a direction was load-bearing. No citation inversion was found in either input. Trail in redteam/claim-audit.md. Adversarial review 2026-10-14: claim C35 reclassified from verified to unverified because its paraphrase of the 2025 Delphi consensus statement is not supported by the accessible PubMed abstract and the full text is paywalled; see finding F1 in ADVERSARIAL REVIEW AND APPROVAL." }, "factual_issues_found": [], "cap_rules_applied": [ { "subclaim_id": "SC1", "cap": "Β", "cap_source": "rubric", "triggered": true, "trigger_text_quoted": "Association-only microbiome work caps at Β.", "specific_trigger": "Human disease-composition differences and covariate studies are observational.", "resulting_ceiling": "Β" }, { "subclaim_id": "SC5", "cap": "Γ", "cap_source": "universal", "triggered": true, "trigger_text_quoted": "Seeding or forced-transfer paradigms cap at Γ for endogenous propagation claims. Forced spread is not observed spread.", "specific_trigger": "Forced rodent transfer and donor FMT cannot alone establish endogenous primary causation across human disease classes.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC5", "cap": "Γ", "cap_source": "rubric", "triggered": true, "trigger_text_quoted": "Any framework that has not crossed the transfer/rescue threshold in vivo", "specific_trigger": "No defined community shift has crossed transfer/rescue for broad human multi-system primacy; narrow clinical effects are separate scopes.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC5", "cap": "Γ", "cap_source": "universal", "triggered": true, "trigger_text_quoted": "Biomarker change without functional/phenotypic change caps at Γ.", "specific_trigger": "The human arm of the carnitine/TMAO withdrawal experiment moves a circulating metabolite, not a clinical endpoint; the cardiovascular endpoint in the same report is observational.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC1", "cap": "Β", "cap_source": "universal", "triggered": true, "trigger_text_quoted": "Pure association evidence - however large, however replicated - cannot exceed Β.", "specific_trigger": "Population cohorts, case-control signatures and diversity metrics, including the prospective cardiovascular association in the TMAO report.", "resulting_ceiling": "Β" } ], "cap_precedence_resolutions": [ { "collision": "The rubric says in-vivo transfer crosses Δ; universal cap 5 limits forced-transfer inference to endogenous human biology.", "subclaim_scope_cap_binds_on": "SC5: broad human primary causation across distant-organ disease classes.", "subclaim_scope_threshold_binds_on": "SC2: selected animal models; SC3/SC4: narrow human treatment scopes.", "resolution": "Transfer crosses a threshold within its tested system. Cap 5 blocks inference to broad endogenous human primacy but does not lower separately scored rodent or CDI subclaims.", "note": "No cap was silently applied to SC2 or SC3." }, { "collision": "The framework names Mendelian randomization as a field-valid equivalent that can carry a claim up the ladder, while rubric 04's own Δ definition names only in-vivo transfer or perturbation and does not list MR among its field-valid equivalents.", "subclaim_scope_cap_binds_on": "SC5: broad human primacy across distant-organ disease classes.", "subclaim_scope_threshold_binds_on": "SC4: a defined microbial function against a human metabolic trait, which is the scope the genetic instrument actually tests.", "resolution": "The framework's enumeration of equivalents is universal and governs reachability; the rubric's list is illustrative for this domain and is not exhaustive. The instrument is therefore admitted, at the scope it tests. It contributes to SC4 and does not reach SC5, where the limiting factor is scope and confounding rather than study design.", "note": "Recorded rather than resolved silently, per the framework's third obligation. Rubric 04's field-valid-equivalent list is flagged as needing revision to name Mendelian randomization." } ], "boundary_check_BGD": [ { "subclaim_id": "SC1", "field_valid_perturbation_quote": "Gnotobiotic or transfer experiment showing phenotype movement, at minimum", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "None for association-only existence.", "gamma_hard_rules_triggered": [ "“Any framework that has not crossed the transfer/rescue threshold in vivo” — triggered; lower Β association cap binds first." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "No causal perturbation is claimed for this subclaim.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC2", "field_valid_perturbation_quote": "Gnotobiotic or transfer experiment showing phenotype movement, at minimum", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "[1]–[5]", "gamma_hard_rules_triggered": [ "Transfer/rescue hard rule not triggered for selected rodent sufficiency." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "Defined colonization, transfer, or resident microbial-function perturbation moved tested phenotypes.", "ceiling_from_boundary_check": "Δ or higher" }, { "subclaim_id": "SC3", "field_valid_perturbation_quote": "Gnotobiotic or transfer experiment showing phenotype movement, at minimum", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "[14]–[15]", "gamma_hard_rules_triggered": [ "Transfer/rescue hard rule not triggered for recurrent CDI niche." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "Randomized restoration reduces recurrence in this depleted gut niche.", "ceiling_from_boundary_check": "Δ or higher" }, { "subclaim_id": "SC4", "field_valid_perturbation_quote": "Gnotobiotic or transfer experiment showing phenotype movement, at minimum", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "[8]-[13], [16], [18], [20]-[21], [31], [36], [38]", "gamma_hard_rules_triggered": [ "Transfer/rescue hard rule not triggered for selected human treatment outcomes." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "Positive randomized results exist alongside null and non-durable outcomes, and a human genetic instrument supports a causal contribution of a defined microbial function to a metabolic trait. Clause 5 is satisfied: at least one field-valid perturbation is positive, and the nulls are scored as nulls rather than as crossings.", "ceiling_from_boundary_check": "Δ or higher" }, { "subclaim_id": "SC5", "field_valid_perturbation_quote": "Gnotobiotic or transfer experiment showing phenotype movement, at minimum", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "No defined transfer/rescue shows incident/progressive disease across distant-organ systems in humans.", "gamma_hard_rules_triggered": [ "“Any framework that has not crossed the transfer/rescue threshold in vivo” - triggered for SC5 scope.", "Universal cap 5 - triggered for inference from forced transfer to endogenous human biology.", "Universal cap 4, “Biomarker change without functional/phenotypic change caps at Γ” - triggered for the human arm of the carnitine/TMAO withdrawal experiment.", "Universal cap 2, “Pure association evidence … cannot exceed Β” - triggered for the cohort cardiovascular and disease-signature evidence." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Narrow treatment transfers do not show broad primary disease causation, and the two field-valid equivalents that do reach human biology stop short: the genetic instrument covers one microbial function against one trait class, and the withdrawal experiment's human endpoint is a metabolite.", "ceiling_from_boundary_check": "Γ" } ], "generalization_check": { "generalization_tested": "yes", "context_boundary_mapped": "yes", "internal_negative_controls": [ "GUT-PARFECT (full text): the off-medication motor score and objective colon transit separate, while twelve prespecified secondary instruments do not, the Parkinson's Fatigue Scale moves against the intervention, and no separation is present before six months.", "Kootte 2017: benefit at six weeks, absent at eighteen, and response predicted by baseline faecal microbiota composition - a responder boundary determinable before the outcome.", "Piwchan 2025: the same six-week-present, twelve-week-absent shape, independently.", "FMT-TRIM: donor bacterial groups engrafted and persisted for twelve weeks without metabolic benefit - the boundary is not engraftment.", "Koopen 2021: no incremental benefit over a Mediterranean diet - part of the boundary is diet.", "Agarwal 2026: FMT not superior to lactulose for minimal hepatic encephalopathy - part of the boundary is existing standard of care.", "Bloom 2011: commensal Bacteroides colonized susceptible and non-susceptible mice equivalently and induced disease only in susceptible hosts; a disease-enriched Enterobacteriaceae isolate failed despite robust colonization - the rodent boundary is host genotype, not abundance.", "Neyrinck 2025 and Daoust 2023: human obesity-donor transfer shifted taxa without the phenotype on a low-fat diet, and a gnotobiotic hepatic phenotype reversed direction with housing sector.", "Recurrent CDI restoration is effective in a deliberately depleted local niche and does not generalize out of it." ], "note": "Mapped limits with incomplete microbial identity is Ε by definition for SC4 and SC3, and the same mapping is what excludes Η for SC2, whose quoted requirement includes 'strong exclusion of diet, housing, batch, and handling confounds'. It does not license SC5: a boundary mapped around several narrow contexts is not evidence for primacy across all of them." }, "falsification_patterns_met": [ { "subclaim_id": "SC4", "pattern": "Phenotype fails to transfer despite community change/engraftment.", "evidence": "FMT-TRIM changed microbial features without significant metabolic benefit; other trials were null or non-durable.", "downgrade_applied": true }, { "subclaim_id": "SC4", "pattern": "Positive effects do not reproduce across contexts or endpoints.", "evidence": "PD trials are mixed; ReSScue and active-comparator HE results were null on primary outcomes.", "downgrade_applied": true }, { "subclaim_id": "SC2", "pattern": "Phenotype fails to transfer.", "evidence": "Transfer of microbiota from human donors with obesity into antibiotic-pretreated mice on a low-fat diet shifted taxa without reproducing the metabolic or behavioural phenotype. This binds the human-donor whole-community line specifically; it does not touch the single-species add-back or the resident-function removal lines.", "downgrade_applied": false }, { "subclaim_id": "SC2", "pattern": "Independent facilities cannot reproduce the finding.", "evidence": "The hepatic phenotype associated with one faecal transfer reversed direction between the gnotobiotic and SPF sectors of a single facility, and human-to-mouse transfer efficiency is itself a documented source of experimental variability. This is the named reason Η is refused for SC2 rather than a reason to leave Ζ.", "downgrade_applied": false } ], "pitfalls_flagged": [ { "subclaim_id": "SC1", "pitfall": "2. Association dressed as mechanism", "where": "Disease-associated taxa cannot establish causality." }, { "subclaim_id": "SC2", "pitfall": "5. Seeding/transfer paradigms treated as evidence of endogenous propagation", "where": "Animal transfers show recipient-model sufficiency, not human primacy." }, { "subclaim_id": "SC5", "pitfall": "1. Mistaking presence for primacy", "where": "Association is not proof of primary cause." }, { "subclaim_id": "SC5", "pitfall": "6. Downstream effect treated as upstream driver", "where": "Treatment response after disease onset does not establish initiation." }, { "subclaim_id": "SC5", "pitfall": "7. Selective generalization", "where": "Rodent and CDI findings do not generalize automatically." }, { "subclaim_id": "SC4", "pitfall": "10. Mechanism conflation", "where": "Metabolites, taxa, barrier, immune pathways, and crude FMT are distinct mechanisms." }, { "subclaim_id": "SC4", "pitfall": "11. Intervention specificity assumed rather than demonstrated", "where": "Donor FMT changes many organisms and metabolites." }, { "subclaim_id": "SC4", "pitfall": "13. Therapeutic effect misread as mechanistic proof", "where": "Treatment-stage benefit is not proof of primary initiation." }, { "subclaim_id": "SC4", "pitfall": "17. Negative field-valid perturbation read as a crossed threshold", "where": "Null ReSScue, metabolic, and PD results remain negative for their endpoints." }, { "subclaim_id": "SC5", "pitfall": "18. Causal-evidence tallies that do not survive an audit", "where": "Positive studies stay within their own scopes." }, { "subclaim_id": "SC5", "pitfall": "22. Scope fitted to the result", "where": "Defined composition is specified before outcomes; no post-hoc responder scope." }, { "subclaim_id": "SC2", "pitfall": "9. Replication confused with reproduction", "where": "Four rodent lines converge, but each is largely a single laboratory's paradigm; independent reproduction across facilities is documented to be fragile." }, { "subclaim_id": "SC4", "pitfall": "16. Failed generalization mistaken for weak evidence", "where": "Triggered by revision B, which read mapped limits as an unmapped boundary and scored Δ where the framework defines Ε. Recorded because the inversion cost a rung." }, { "subclaim_id": "SC5", "pitfall": "8. Confirmation by biomarker", "where": "The human arm of the carnitine/TMAO withdrawal experiment ends at a circulating metabolite; cap 4 holds it at Γ." }, { "subclaim_id": "SC5", "pitfall": "12. Temporal order inferred rather than demonstrated", "where": "Every human interventional record enrolled people already diagnosed or already in a defined risk state; none establishes that a community shift preceded onset." } ], "causal_tally_audit": { "tally_claimed_by_document": 17, "tally_after_audit": 18, "items_rejected": [ "Grading A reported 17 of 24 intervention papers favourable on its 27-source ledger; recounted against the 39-source union ledger there are 28 intervention or perturbation records, of which 18 report a favourable direction on at least one stated endpoint inside their own bounded system, 8 are null on a relevant primary endpoint, and 2 are context-dependent (direction depends on housing or diet). A's arithmetic on its own ledger was sound.", "These are records, not independent lines for SC5, which has none. Animal interventions count only for SC2; CDI trials count only for SC3; human treatment-stage trials and the genetic instrument count only for SC4.", "Observational associations, including the prospective cardiovascular association in the TMAO report, are excluded from the causal tally.", "The single-arm melanoma FMT trial is counted as a record but not as a controlled perturbation: it has no randomized comparator." ] }, "steelman": { "case_one_rung_higher": "The case for Δ at the graded scope is stronger than either input recorded and deserves to be put at full strength. Two field-valid equivalents reach human biology directly. Bidirectional Mendelian randomization finds host-genetics-driven gut butyrate production associated with improved insulin response, and abnormal propionate handling causally related to type 2 diabetes risk - a human genetic instrument, the first equivalent the framework names, pointing at a systemic metabolic endpoint. Suppressing the intestinal microbiota in human volunteers abolishes production of a proatherogenic microbial metabolite and it returns on recovery - a withdrawal-and-rechallenge experiment in people, the framework's fourth named equivalent - while the same mechanism accelerates atherosclerosis in mice and the metabolite predicts cardiac events in a cohort of thousands. Add randomized human transplant trials that move motor scores in Parkinson disease and insulin sensitivity in metabolic syndrome, and four rodent lines that move arthritis, hepatic tumours and motor phenotypes by defined strains and defined microbial functions. That is human genetics, human pharmacological withdrawal, human randomized intervention and animal perturbation - four classes, each excluding a confounder the others cannot, which is the convergence pattern the framework says Ζ exists for and which certainly clears Δ.", "case_one_rung_lower": "The case for Β is that the broad human evidence is overwhelmingly observational; that diet, transit time and medication are demonstrated determinants of the composition offered as the cause, with stool consistency the largest single source of variation in population cohorts and metformin sufficient to manufacture a type 2 diabetes signature; that randomized transplant results are small, mixed, mostly transient and never use a defined product; and that the one unambiguous human success is an intestinal infection in a niche emptied by antibiotics.", "which_rejected": "Δ is rejected for the graded primacy scope, while Δ or higher is retained in the narrower scopes that earned it: Ζ in selected rodent models, Ε in recurrent CDI, Ε in selected human treatment contexts. Β is rejected because it cannot accommodate four converging rodent perturbation lines, two randomized CDI trials, several positive randomized distant-organ results and a human genetic instrument.", "blocking_cap_threshold_or_missing_experiment": "Three named blockers, in order. (1) Universal cap 4, 'Biomarker change without functional/phenotypic change caps at Γ': the human arm of the withdrawal experiment ends at a circulating metabolite, and its clinical endpoint is observational, which universal cap 2 holds at Β. (2) Scope: the genetic instrument tests one microbial function against one trait class in one cohort, partly confounded with host absorption, so it cannot speak to primacy across disease classes - and the framework's own warning applies, that a set assembled to cover each other's weaknesses is not the same as a set that happens to point the same way at different scopes. (3) Boundary-check clause 5: no field-valid perturbation of a prespecified human community feature has returned a positive incident-disease result at all, because no such experiment has been run before onset. Universal cap 5 then blocks the forced-transfer evidence from filling that gap by inference." }, "final_score": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Moderate", "confidence_rationale": "Multiple causal animal lines, strong human CDI trials, and emerging but conflicting human systemic interventions support the narrow mechanisms; broad human primacy is not directly tested.", "rests_on_non_peer_reviewed_work": false, "rationale": "Gut communities can causally modify selected animal phenotypes and recurrent CDI, with mixed context-specific human metabolic, hepatic, and Parkinson signals. No evidence establishes community composition as a primary cause across human distant-organ disease classes." }, "role_of_mechanism": { "classification": "reinforcing / stabilizing factor", "derivation_step_matched": "5", "derivation": "Step 5: community shifts may amplify, accelerate, or maintain phenotypes initiated by host genotype, diet, medication, transit, infection, or established disease; initiation and rate-limiting primacy are not demonstrated.", "tournament_used_as_tiebreaker": false, "note": "Derived from direction of causation, not tournament rank.", "context_note": "This classification applies to the graded distant-organ primacy claim. It does not describe every context in the review: within recurrent C. difficile infection (SC3), restoration of colonization resistance is a primary driver, and the review's own SC3 scope records that this is local rather than distant-organ. A single role value for a multi-scope hypothesis necessarily reports the graded scope only." }, "extended_scoring_MSD": { "momentum": { "value": "Mechanistic only", "artifact": "2024-2026 randomized Parkinson FMT trials (five; three positive and two null on their primary or prespecified motor endpoints), the 2025-2026 hepatic-encephalopathy trials, and the metabolic transplant series. Population-scale microbiome genetics continues, but no group has announced a pre-onset defined-community perturbation with incident distant-organ endpoints.", "justification": "Trials perturb human communities but test context-specific treatment response, not broad primary causation." }, "stability": { "value": "Stable", "trigger": "No named pending result identified that directly resolves multi-system human primacy.", "justification": "Recent human signals are mixed by disease, endpoint, intervention, and duration." }, "divergence": { "implied_level": null, "implied_level_basis": "Withdrawn 2026-10-14. The Ζ reading rested solely on claim C35, whose paraphrase of the 2025 Delphi consensus statement is not supported by the accessible PubMed abstract and whose full text is paywalled. No single implied level is establishable on the checkable record: the only other field-facing source [34] frames the field at or below the assessed Γ. This review does not assert that the consensus statement says the opposite, only that the reading is not checkable.", "assessed_level": "Γ", "gap_in_rungs": null, "value": "Contested", "justification": "Two field-facing sources point in opposite directions and the stronger one is unverifiable, which is the case the framework assigns to Contested: the field is genuinely split and no single implied level applies, so no rung arithmetic is available. Recorded as unresolved pending full-text access to source 35. Divergence modifies neither the level nor the confidence band.", "dissent_recorded": "Grading A returned Severe overstatement with a gap of 4, computed from the claim's wording implying Η; the framework requires the implied level to come from field framing, so the method is rejected even though the label is the same. Revision B returned Substantial overstatement with a gap of +2, inferring Ε from two field-facing sources; the method is right and is adopted, but the value is rejected - B measured the field's framing of the narrow context-specific claim against the assessed level of the broad claim, and neither cited source says Ε for the broad claim.", "revision_note": "Revised by adversarial review 2026-10-14 (finding F1) from \"Severe overstatement\", implied Ζ, gap +3. The prior value and its derivation are preserved in sol61-original/." }, "calibration_note": "M/S/D do not modify HSEF level or confidence. Divergence was recomputed after the level was locked." }, "change_record": { "applies": true, "prior_level": "Γ (both inputs)", "prior_confidence": "Moderate (both inputs)", "prior_source": "Grading A (OpenAI Codex, schema 5.3, as corrected by a prior light red-team pass) and revision B (OpenAI Codex, schema 5.4, revision mode of A).", "derived_before_consulting_prior": true, "new_level": "Γ", "new_confidence": "Moderate", "direction": "held", "what_moved_it": "Nothing moved the overall letter: the graded claim is primacy across human distant-organ disease classes, and no field-valid perturbation of a prespecified human community feature has returned a positive incident-disease result at that scope. Beneath the letter, three changes relative to revision B and four relative to grading A. Against B: SC2 restored to Ζ (B applied Η's 'narrowed mechanism' requirement at Ζ, and differing mechanisms establish independence rather than defeating it); the human-treatment subclaim restored to Ε (B inverted pitfall 16 after removing five of the six trials that map the boundary); the recurrent-CDI subclaim restored (the index prescribes reporting it separately). Against A: Divergence recomputed from field framing rather than from the claim's wording, giving an implied level of Ζ and a gap of +3 - the same verdict label by a different route, and against B's +2; two false absence claims in the upper-ladder check overturned by a human Mendelian-randomization instrument and a human withdrawal experiment, both of which run for the hypothesis and neither of which crosses the threshold, for named reasons; the failed-transfer and housing-reversal evidence admitted, which is why Η is now explicitly refused for SC2; and a lay summary added, which was A's only validator failure.", "divergence_from_other_reviewers": "Both input gradings returned Γ / Moderate and this synthesis holds it. The disagreements are beneath the letter and all of them are carried in the posted edition: SC2 Ζ vs Ε, human-treatment Ε vs Δ, five subclaims vs four, 39 sources vs 27 vs 15, and Divergence +3 vs 4 vs +2. Where this pass disagrees with the newer file it says so and gives the rule; where the newer file was right - its lay summary, its Divergence method, and three sources showing that rodent transfer is less robust than grading A's ledger implied - it is adopted." }, "proposed_decisive_experiments": [ { "name": "Pre-onset test of defined-community primacy", "experiment": "In a prespecified high-risk population, perturb a defined microbial feature - a strain-resolved consortium or a named microbial function - before disease onset, verify target engagement longitudinally, and follow incident distant-organ disease in at least two organ systems.", "readout": "Incident distant-organ disease, with longitudinal measurement of the microbial target, host state, diet, medication and transit.", "critical_control": "Pre-outcome eligibility, blinded endpoint adjudication, negative controls, independent replication, and reversal or add-back evidence where feasible.", "falsifying_result": "Verified target engagement without change in incident outcomes, or host and disease changes preceding the microbial shift.", "supporting_result": "A defined shift precedes and reproducibly changes incident disease across organ classes, with narrowed mediation and rescue." }, { "name": "Independent replication of a human treatment-stage transfer effect, with add-back logic", "experiment": "Replicate the strongest existing signal - the Parkinson motor result or the six-week metabolic result - multicentre and blinded, with a defined product rather than whole stool, prespecified durability endpoints beyond the point at which current effects fade, and a removal or add-back arm.", "readout": "Target engagement plus the prespecified organ-specific clinical outcome, with host, diet, medication and transit measured.", "critical_control": "Co-transferred metabolites, bowel preparation, concomitant treatment and donor variability.", "falsifying_result": "Target engagement without the predicted clinical effect across sites.", "supporting_result": "Reproducible phenotype movement tied to the prespecified feature, with add-back or rescue evidence." }, { "name": "Mendelian randomization on composition rather than on a single microbial function", "experiment": "Instrument community-composition features directly, with sensitivity analyses against host pleiotropy at the known loci, across independent cohorts and against more than one distant-organ endpoint.", "readout": "Causal estimates for composition features against incident distant-organ disease endpoints, replicated across cohorts.", "critical_control": "Weak-instrument diagnostics, pleiotropy-robust estimators, and explicit handling of the host loci that dominate microbiome GWAS.", "falsifying_result": "Null causal estimates for composition features where the equivalent function-level instruments are positive.", "supporting_result": "Replicated causal estimates for prespecified composition features against more than one distant-organ endpoint - the cheapest available route to Δ at the graded scope." } ], "knowledge_gaps": [ { "name": "Human temporal direction", "statement": "Every human interventional record enrolled people already diagnosed or already in a defined risk state; nothing tests whether a community shift precedes onset.", "relevance": "This is the gap that holds SC5 at Γ." }, { "name": "Defined causal identity", "statement": "Most clinical trials transfer whole communities; the responsible organisms or functions remain unresolved, and whole-stool transfer cannot identify them in principle.", "relevance": "This is why SC3 and SC4 stop at Ε rather than Ζ." }, { "name": "Competing upstream factors", "statement": "Diet, transit, medication, host physiology, genotype and established disease all reshape composition, and the first two have been shown to do so experimentally.", "relevance": "Model 1 remains the best-supported rival for this reason." }, { "name": "Generalization boundaries in humans", "statement": "The limits are mapped on the time and engraftment axes and partly on the diet axis; why the Parkinson trials disagree with each other is not explained by any mapped variable.", "relevance": "Mapped-but-incomplete is exactly Ε's description." }, { "name": "Rodent reproducibility", "statement": "Housing sector can reverse the sign of a transfer phenotype and transfer efficiency varies between recipients.", "relevance": "This is the named reason SC2 stops below Η." } ], "review_metadata": { "review_date": "2026-09-27", "reviewer": "Red-team synthesis: Claude (Anthropic), independent model, 2026-09-27", "input_graders": [ "Grading A - OpenAI Codex, HSEF schema 5.3, validator 2.3, plus a prior light red-team pass (archived as A_posted_2026-09-27)", "Revision B - OpenAI Codex, HSEF schema 5.4, validator 2.4, revision mode of A (archived as B_v5.4_revision)" ], "evidence_base_note": "Primary peer-reviewed studies sampled through 2026-09-27; the union of both inputs' ledgers plus four omission-audit additions. Not a systematic review.", "literature_tools_available": true, "literature_tools_note": "PubMed/NCBI records and abstracts retrieved for all 39 rows; PMC or publisher full text read where a figure or a direction was load-bearing. Scite citation-context data were unavailable and were not used to assign levels.", "skill_version": "5.4", "validator_run": "pass", "validator_warnings_addressed": "Lay summary added; ledger identifiers completed on every row; access depth corrected where a claim rested on full text; independence lines labelled by subclaim; provenance header regenerated from the ledger.", "consensus_consistency_audit": "2026-10-09; supplementary provenance/source reconciliation; original grading retained; prior grades visible." }, "is_calibration_entry": { "value": false, "entry_role": "not_calibration", "blind_graded": null, "completed_blinded_calibration": false, "expected_band_sealed_at": "", "target_sha256": "", "target_authorship": "No sealed target supplied", "target_author_saw_review": null, "future_run_status": "not prepared", "unblinded_reason": "Standalone assessment; no sealed calibration target was supplied, so no blind calibration run occurred." }, "upper_ladder_check": { "final_level_below_zeta": true, "equivalents_considered": [ { "kind": "mendelian_randomization", "available": true, "evidence": "Ledger 36: bidirectional MR in 952 normoglycaemic individuals; host-genetics-driven butyrate production associated with improved insulin response; abnormal propionate production or absorption causally related to type 2 diabetes risk (P = 0.004).", "why_not_sufficient": "A genuine human genetic instrument, and it is why SC4 is Ε rather than Δ. It instruments a microbial function rather than community composition, is partly confounded with host absorption, covers one trait class in one cohort, and therefore cannot establish primacy across distant-organ disease classes. Grading A recorded this equivalent as unavailable; that was wrong and is corrected." }, { "kind": "natural_experiment", "available": false, "why_not_sufficient": "No endogenous human composition shift preceding multi-system disease with credible exclusion of confounding was identified. Antibiotic exposure is the obvious candidate and is not clean: it perturbs the host directly and is prescribed for conditions that independently predict outcomes." }, { "kind": "dose_response_across_populations", "available": true, "why_not_sufficient": "Cohort gradients are observational and capped at Β; no replicated cross-population dose-response of a defined microbial feature against a distant-organ endpoint exists." }, { "kind": "withdrawal_rechallenge", "available": true, "evidence": "Ledger 37: suppressing the intestinal microbiota in human volunteers abolished carnitine-derived TMAO production, which returned as the microbiota recovered; microbiota suppression also abolished the carnitine-driven acceleration of atherosclerosis in mice.", "why_not_sufficient": "The human endpoint is a circulating metabolite, so universal cap 4 binds - 'Biomarker change without functional/phenotypic change caps at Γ' - while the human clinical endpoint in the same report is an observational association capped at Β and the disease endpoint is in mice. Three components, three caps, no crossing. Grading A recorded this equivalent as unavailable; that was wrong and is corrected." }, { "kind": "therapeutic_perturbation_hard_endpoint", "available": true, "why_not_sufficient": "Recurrent CDI is a hard endpoint and a randomized success, but it is a local intestinal infection in a deliberately depleted niche. Parkinson, hepatic and metabolic interventions are context-specific and mixed, use undefined products, and begin after diagnosis; the melanoma FMT result is single-arm." } ], "convergence_present": true, "cap_reapplied_to_convergent_set": false, "convergence_note": "The framework's rule that a convergent set is not re-capped was applied and then tested against pitfall 21. Human genetics, human withdrawal, human randomized intervention and animal perturbation do each exclude a confounder the others cannot - but they converge on different claims at different scopes (one microbial function and a metabolic trait; a metabolite; treatment-stage symptom change; rodent phenotypes), not on the graded claim. No cap is re-applied to the set; the set simply does not cover the graded scope." }, "provenance_header": { "sources_total": 39, "claims_total": 39, "claims_verified": 38, "claims_unverified": 1, "claims_contradicted": 0, "tier_a_sources": 37, "generated_by": "HSEF review workflow v5.4; validator 2.4; red-team synthesis by Claude (Anthropic), independent model, 2026-09-27, over two OpenAI Codex gradings", "gate_passed": false, "gate_note": "Set false by adversarial review 2026-10-14: the unresolved set is non-empty (claim C35 is unverified, finding F1). The validator requires gate_passed false while any claim is unresolved. No numeric claim is affected - C35 carries_number is false - and the level, confidence, role and subclaims are unchanged." }, "claims": [ { "id": "C1", "text": "In K/BxN mice, SFB reintroduction restored Th17 responses, autoantibodies, and arthritis in a susceptible host model.", "carries_number": true, "load_bearing_for": [ "SC2" ], "source_ns": [ 1 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Primary publication; full text not claimed unless access_depth says otherwise." }, { "id": "C2", "text": "Human twin-derived microbiota transferred adiposity and metabolic phenotypes to germ-free mice, with diet-dependent effects and lean-community protection on cohousing.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 2 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Primary publication; full text not claimed unless access_depth says otherwise." }, { "id": "C3", "text": "Bacteroides fragilis treatment altered gut barrier and behavioral/physiological phenotypes in a maternal-immune-activation mouse model.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 3 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Primary publication; full text not claimed unless access_depth says otherwise." }, { "id": "C4", "text": "E. gallinarum translocation promoted autoimmune pathology in susceptible mice; human biopsy observations were not a causal intervention.", "carries_number": false, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 4 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Primary publication; full text not claimed unless access_depth says otherwise." }, { "id": "C5", "text": "In obese, carcinogen-exposed mice, microbiota-derived DCA promoted liver cancer signaling and bacterial reduction or DCA blockade reduced tumor development.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 5 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Primary publication; full text not claimed unless access_depth says otherwise." }, { "id": "C6", "text": "Bacteroides induced colitis only in susceptible mouse genotypes; a disease-enriched Enterobacteriaceae isolate failed to induce disease despite colonization.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 6 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Primary publication; full text not claimed unless access_depth says otherwise." }, { "id": "C7", "text": "Human IBD microbiota behavior in mouse transfer models depended on prior mouse adaptation and recipient inflammatory environment.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 7 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Primary publication; full text not claimed unless access_depth says otherwise." }, { "id": "C8", "text": "Lean-donor FMT improved insulin sensitivity at six weeks in some men with MetS, but the benefit was absent at 18 weeks.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 8 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Primary publication; full text not claimed unless access_depth says otherwise." }, { "id": "C9", "text": "In a 24-person randomized pilot, FMT changed microbiota but did not significantly improve insulin sensitivity or metabolic outcomes.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 9 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Primary publication; full text not claimed unless access_depth says otherwise." }, { "id": "C10", "text": "In 24 men with MetS, diet effects were evident and lean-donor FMT added no significant benefit on measured metabolic endpoints.", "carries_number": true, "load_bearing_for": [ "SC4", "SC5" ], "source_ns": [ 10 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Primary publication; full text not claimed unless access_depth says otherwise." }, { "id": "C11", "text": "A 31-person, three-arm randomized T2D study reported four-week improvements in HOMA-IR and BMI after FMT with donor-derived community changes.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 11 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Primary publication; full text not claimed unless access_depth says otherwise." }, { "id": "C12", "text": "In 8 FMT and 10 sham participants, HOMA-IR improved at 6 weeks (MAD −1.63; 95% CI −2.63 to −0.64; p=.001), but not at 12 weeks.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 12 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Primary publication; full text not claimed unless access_depth says otherwise." }, { "id": "C13", "text": "A 32-woman randomized trial found microbiota composition changed after FMT but no clinical or biochemical improvement versus sham over one year.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 13 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Primary publication; full text not claimed unless access_depth says otherwise." }, { "id": "C14", "text": "In recurrent CDI after antibiotics, donor fecal infusion improved resolution compared with antibiotic-only arms.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 14 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Primary publication; full text not claimed unless access_depth says otherwise." }, { "id": "C15", "text": "In a phase III trial of 182 patients, recurrent CDI was 12% after purified Firmicutes spores versus 40% after placebo (RR .32; 95% CI .18–.58).", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 15 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Primary publication; full text not claimed unless access_depth says otherwise." }, { "id": "C16", "text": "In 60 patients, primary outcome was safety; HE recurrence differed on secondary analysis (p=.035) and post hoc any-FMT vs all-placebo (9% vs 40%).", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 16 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Primary publication; full text not claimed unless access_depth says otherwise." }, { "id": "C17", "text": "In 130 randomized and 122 analyzed, minimal HE resolution was 68.3% with FMT vs 66.1% with lactulose (risk difference 2.2%; 95% CI −14.4 to 18.9; p=.80).", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 17 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Primary publication; full text not claimed unless access_depth says otherwise." }, { "id": "C18", "text": "In 46 randomized patients, off-medication motor score improved more after donor than autologous FMT at 12 months (p=.0235); most other scales did not differ.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 18 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Primary publication; full text not claimed unless access_depth says otherwise." }, { "id": "C19", "text": "In a multicenter Finnish trial (45 ITT), FMT did not improve the primary PD outcome at 6 months (difference .97; 95% CI −5.10 to 7.03; p=.75).", "carries_number": true, "load_bearing_for": [ "SC4", "SC5" ], "source_ns": [ 19 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Primary publication; full text not claimed unless access_depth says otherwise." }, { "id": "C20", "text": "In a 30-person single-center trial, fresh FMT was associated with improved motor and nonmotor scores at 12 weeks vs saline.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 20 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Primary publication; full text not claimed unless access_depth says otherwise." }, { "id": "C21", "text": "In 72 randomized and 66 completed, repeated donor FMT improved UPDRS III at week 35 vs autologous FMT (mean change −3.8 vs +0.1; p=.0001).", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 21 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Primary publication; full text not claimed unless access_depth says otherwise." }, { "id": "C22", "text": "In 59 randomized participants, donor FMT did not improve primary off-state MDS-UPDRS III at 12 months (difference 1.50; 95% CI −4.28 to 7.28; p=1.00).", "carries_number": true, "load_bearing_for": [ "SC4", "SC5" ], "source_ns": [ 22 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Primary publication; full text not claimed unless access_depth says otherwise." }, { "id": "C23", "text": "In 67 participants, standardized cultured microbiome infusion did not improve worst lower-GI symptom at 12 weeks vs placebo (p=.22).", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 23 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Primary publication; full text not claimed unless access_depth says otherwise." }, { "id": "C24", "text": "Analysis of 784 human metagenomes found metformin treatment confounded microbiome signatures attributed to T2D.", "carries_number": true, "load_bearing_for": [ "SC1", "SC5" ], "source_ns": [ 24 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Primary publication; full text not claimed unless access_depth says otherwise." }, { "id": "C25", "text": "Stool consistency, a transit proxy, was strongly associated with microbiome metrics in healthy women.", "carries_number": false, "load_bearing_for": [ "SC1", "SC5" ], "source_ns": [ 25 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Primary publication; full text not claimed unless access_depth says otherwise." }, { "id": "C26", "text": "Large cohorts identified stool consistency and medication among major sources of microbiome variation.", "carries_number": false, "load_bearing_for": [ "SC1", "SC5" ], "source_ns": [ 26 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Primary publication; full text not claimed unless access_depth says otherwise." }, { "id": "C27", "text": "Metformin changed the microbiome in untreated T2D; stool from treated participants improved glucose tolerance in germ-free mice.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC5" ], "source_ns": [ 27 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Primary publication; full text not claimed unless access_depth says otherwise." }, { "id": "C28", "text": "Germ-free or antibiotic-treated alpha-synuclein-overexpressing mice show reduced motor deficits and microglial activation; recolonization, or oral administration of microbial short-chain fatty acids, restores them.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 28 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Third independent rodent line for SC2: removal plus add-back with a defined metabolite class." }, { "id": "C29", "text": "Transfer of microbiota from human donors with obesity into antibiotic-pretreated mice on a low-fat diet shifted taxa and caecal microbial metabolites without reproducing the metabolic or behavioural phenotype of obesity.", "carries_number": false, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 29 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "A failed transfer. Falls inside the diet-dependence the twin-transfer study itself reported, rather than contradicting it." }, { "id": "C30", "text": "The hepatic phenotype associated with one faecal transfer into gnotobiotic mice reversed direction between the germ-free and the specific-pathogen-free sector of the same facility.", "carries_number": false, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 30 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Housing as a decisive confounder; the named reason Η is refused for SC2." }, { "id": "C31", "text": "Infusion of lean-donor intestinal microbiota improved insulin sensitivity at six weeks in men with metabolic syndrome, alongside increased butyrate-producing taxa.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 31 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "The founding positive human metabolic transfer result. No figure carried; the record was read at abstract depth." }, { "id": "C32", "text": "Switching people between entirely animal-based and entirely plant-based diets rapidly and reproducibly altered gut community structure and overwhelmed inter-individual differences in microbial gene expression.", "carries_number": false, "load_bearing_for": [ "SC1", "SC5" ], "source_ns": [ 32 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Interventional, not observational: composition is demonstrably downstream of diet." }, { "id": "C33", "text": "Colonic transit time is associated with overall community composition, richness, and a shift from carbohydrate fermentation to protein catabolism.", "carries_number": false, "load_bearing_for": [ "SC1", "SC5" ], "source_ns": [ 33 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Transit as a determinant of the measured community." }, { "id": "C34", "text": "A 2024 field review places established human causal evidence in recurrent C. difficile infection, ulcerative colitis and cancer-immunotherapy response, and reports that microbiome-therapeutic trials in obesity have not improved weight or body-mass index.", "carries_number": false, "load_bearing_for": [ "SC4", "SC5" ], "source_ns": [ 34 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Tier B: field framing and divergence basis only. Figures in the source are deliberately not carried." }, { "id": "C35", "text": "A 2025 Delphi consensus statement of the field reports that the evidence strongly supported a causal role for the gut microbiome in inflammatory bowel disease, obesity, type 2 diabetes and liver diseases, while recording that animal models do not entirely replicate the human gut microbiome and that their translational potential is rather limited.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 35 ], "verification": "unverified", "verified_against": "disputed on the accessible record (2026-10-14): the PubMed abstract describes a Delphi survey of the utility of preclinical models, says composition disruption \"is implicated in\" various conditions, and states that establishing cause and effect \"is extremely difficult\"; the full text is paywalled with no PMC copy, so what the consensus statements say about field belief is neither confirmed nor denied. The clause on limited translational potential of animal models is consistent with the abstract.", "verified_on": "2026-09-27", "note": "Tier B: the Divergence basis. Its per-disease consensus percentages are deliberately not carried, because a Tier B source may not carry a number. Reclassified unverified by adversarial review 2026-10-14 (finding F1); the Divergence artifact no longer rests on it." }, { "id": "C36", "text": "Bidirectional Mendelian randomization in 952 normoglycaemic individuals found host-genetics-driven gut butyrate production associated with improved insulin response after an oral glucose-tolerance test, and abnormalities in propionate production or absorption causally related to increased type 2 diabetes risk (P = 0.004).", "carries_number": true, "load_bearing_for": [ "SC4", "SC5" ], "source_ns": [ 36 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "The butyrate p-value is truncated in the retrieved record and is not carried; only the propionate value, which is complete in the record, is stated." }, { "id": "C37", "text": "Suppressing the intestinal microbiota with antibiotics abolished carnitine-derived trimethylamine-N-oxide production in human volunteers and it returned as the microbiota recovered; microbiota suppression also abolished the carnitine-driven acceleration of atherosclerosis in mice, while the human cardiovascular endpoint in the same report is an observational association.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 37 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "A human withdrawal-and-rechallenge experiment whose human endpoint is a metabolite; cap 4 binds." }, { "id": "C38", "text": "In an open-label randomized trial in cirrhosis with recurrent hepatic encephalopathy, no faecal-transplant recipient and five standard-of-care recipients developed a further episode (P = 0.03), with fewer serious adverse events in the transplant arm.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 38 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "Open-label, twenty participants, and the transplant arm received antibiotic pretreatment - recorded because those are the limits, not footnotes." }, { "id": "C39", "text": "In a single-arm phase II trial, responder-derived faecal transplant with anti-PD-1 produced clinical benefit in 6 of 15 patients with PD-1-refractory melanoma.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 39 ], "verification": "verified", "verified_against": "PubMed abstract or publisher record", "verified_on": "2026-09-27", "note": "No randomized comparator: counted as a record, not as a controlled perturbation." } ], "citation_ledger": [ { "n": 1, "citation": "Wu HJ et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity. 2010;32:815–827.", "tier": "A", "kind": "primary", "pmid": "20620945", "doi": "10.1016/j.immuni.2010.06.001", "url": "https://pubmed.ncbi.nlm.nih.gov/20620945/", "status_flags": [ "none_found" ], "carries_claims": [ "C1" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:20620945", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted." }, { "n": 2, "citation": "Ridaura VK et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013;341:1241214.", "tier": "A", "kind": "primary", "pmid": "24009397", "doi": "10.1126/science.1241214", "url": "https://pubmed.ncbi.nlm.nih.gov/24009397/", "status_flags": [ "none_found" ], "carries_claims": [ "C2" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:24009397", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted." }, { "n": 3, "citation": "Hsiao EY et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell. 2013;155:1451–1463.", "tier": "A", "kind": "primary", "pmid": "24315484", "doi": "10.1016/j.cell.2013.11.024", "url": "https://pubmed.ncbi.nlm.nih.gov/24315484/", "status_flags": [ "none_found" ], "carries_claims": [ "C3" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:24315484", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted." }, { "n": 4, "citation": "Manfredo Vieira S et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans. Science. 2018;359:1156–1161.", "tier": "A", "kind": "primary", "pmid": "29590047", "doi": "10.1126/science.aar7201", "url": "https://pubmed.ncbi.nlm.nih.gov/29590047/", "status_flags": [ "none_found" ], "carries_claims": [ "C4" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:29590047", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted." }, { "n": 5, "citation": "Yoshimoto S et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013;499:97–101.", "tier": "A", "kind": "primary", "pmid": "23803760", "doi": "10.1038/nature12347", "url": "https://pubmed.ncbi.nlm.nih.gov/23803760/", "status_flags": [ "none_found" ], "carries_claims": [ "C5" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:23803760", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted." }, { "n": 6, "citation": "Bloom SM et al. Commensal Bacteroides species induce colitis in host-genotype-specific fashion in a mouse model of inflammatory bowel disease. Cell Host Microbe. 2011;9:390–403.", "tier": "A", "kind": "primary", "pmid": "21575910", "doi": "10.1016/j.chom.2011.04.009", "url": "https://pubmed.ncbi.nlm.nih.gov/21575910/", "status_flags": [ "none_found" ], "carries_claims": [ "C6" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:21575910", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted." }, { "n": 7, "citation": "Gray SM et al. Mouse adaptation of human inflammatory bowel diseases microbiota enhances colonization efficiency and alters microbiome aggressiveness depending on the recipient colonic inflammatory environment. Microbiome. 2024;12(1):147.", "tier": "A", "kind": "primary", "pmid": "39113097", "doi": "10.1186/s40168-024-01857-2", "url": "https://pubmed.ncbi.nlm.nih.gov/39113097/", "status_flags": [ "none_found" ], "carries_claims": [ "C7" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:39113097", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted." }, { "n": 8, "citation": "Kootte RS et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metabolism. 2017;26:611–619.e6.", "tier": "A", "kind": "rct", "pmid": "28978426", "doi": "10.1016/j.cmet.2017.09.008", "url": "https://pubmed.ncbi.nlm.nih.gov/28978426/", "status_flags": [ "none_found" ], "carries_claims": [ "C8" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:28978426", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted." }, { "n": 9, "citation": "Yu EW et al. Fecal microbiota transplantation for the improvement of metabolism in obesity: The FMT-TRIM double-blind placebo-controlled pilot trial. PLoS Med. 2020;17(3):e1003051.", "tier": "A", "kind": "rct", "pmid": "32150549", "doi": "10.1371/journal.pmed.1003051", "url": "https://pubmed.ncbi.nlm.nih.gov/32150549/", "status_flags": [ "none_found" ], "carries_claims": [ "C9" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:32150549", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted.", "redteam_note": "Post-verification: citation title was shortened or paraphrased; replaced with the exact PubMed title, re-verified 2026-09-27." }, { "n": 10, "citation": "Koopen AM et al. Effect of Fecal Microbiota Transplantation Combined With Mediterranean Diet on Insulin Sensitivity in Subjects With Metabolic Syndrome. Front Microbiol. 2021;12:662159.", "tier": "A", "kind": "rct", "pmid": "34177842", "doi": "10.3389/fmicb.2021.662159", "url": "https://pubmed.ncbi.nlm.nih.gov/34177842/", "status_flags": [ "none_found" ], "carries_claims": [ "C10" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:34177842", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted.", "redteam_note": "Post-verification: citation title was shortened or paraphrased; replaced with the exact PubMed title, re-verified 2026-09-27." }, { "n": 11, "citation": "Wu Z et al. Fecal microbiota transplantation reverses insulin resistance in type 2 diabetes: A randomized, controlled, prospective study. Front Cell Infect Microbiol. 2023;12:1089991.", "tier": "A", "kind": "rct", "pmid": "36704100", "doi": "10.3389/fcimb.2022.1089991", "url": "https://pubmed.ncbi.nlm.nih.gov/36704100/", "status_flags": [ "none_found" ], "carries_claims": [ "C11" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:36704100", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted.", "redteam_note": "Post-verification: citation title was shortened or paraphrased; replaced with the exact PubMed title, re-verified 2026-09-27." }, { "n": 12, "citation": "Piwchan S et al. Fecal Microbiota Transplantation by Rectal Enema Improves Short-Term Insulin Resistance in Metabolic Syndrome: A Pilot Randomized Controlled Trial. J Obes Metab Syndr. 2025;34(4):434–445.", "tier": "A", "kind": "rct", "pmid": "40916606", "doi": "10.7570/jomes25014", "url": "https://pubmed.ncbi.nlm.nih.gov/40916606/", "status_flags": [ "none_found" ], "carries_claims": [ "C12" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:40916606", "access_depth": "full_text_partial", "access_note": "Publisher/PubMed full text sections read; no complete supplement audit claimed.", "redteam_note": "Post-verification: citation title was shortened or paraphrased; replaced with the exact PubMed title, re-verified 2026-09-27." }, { "n": 13, "citation": "da Ponte Neto AM et al. Fecal microbiota transplantation in patients with metabolic syndrome and obesity: a randomized controlled trial. World J Clin Cases. 2023;11(19):4612–4624.", "tier": "A", "kind": "rct", "pmid": "37469721", "doi": "10.12998/wjcc.v11.i19.4612", "url": "https://pubmed.ncbi.nlm.nih.gov/37469721/", "status_flags": [ "none_found" ], "carries_claims": [ "C13" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:37469721", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted.", "redteam_note": "Prior pass filled the DOI. This pass found the row still carried no author and no journal, making it unreconstructable from the page; the full citation was resolved in PubMed on 2026-09-27 and written in." }, { "n": 14, "citation": "van Nood E et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407–415.", "tier": "A", "kind": "rct", "pmid": "23323867", "doi": "10.1056/NEJMoa1205037", "url": "https://pubmed.ncbi.nlm.nih.gov/23323867/", "status_flags": [ "none_found" ], "carries_claims": [ "C14" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:23323867", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted." }, { "n": 15, "citation": "Feuerstadt P et al. SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med. 2022;386(3):220–229.", "tier": "A", "kind": "rct", "pmid": "35045228", "doi": "10.1056/NEJMoa2106516", "url": "https://pubmed.ncbi.nlm.nih.gov/35045228/", "status_flags": [ "none_found" ], "carries_claims": [ "C15" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:35045228", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted.", "redteam_note": "Post-verification: citation title was shortened or paraphrased; replaced with the exact PubMed title, re-verified 2026-09-27. The PubMed API strips the italicised organism from this title, returning “for RecurrentInfection”; the published title reads “for Recurrent Clostridioides difficile Infection” and is written in full here." }, { "n": 16, "citation": "Bajaj JS et al. Microbiota transplant for hepatic encephalopathy in cirrhosis: The THEMATIC trial. J Hepatol. 2025;83:81–91.", "tier": "A", "kind": "rct", "pmid": "39800192", "doi": "10.1016/j.jhep.2024.12.047", "url": "https://pubmed.ncbi.nlm.nih.gov/39800192/", "status_flags": [ "none_found" ], "carries_claims": [ "C16" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:39800192", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted." }, { "n": 17, "citation": "Agarwal A et al. Impact of two-session fecal microbiota transplantation on minimal hepatic encephalopathy in cirrhosis. World J Hepatol. 2026;18(4):116153.", "tier": "A", "kind": "rct", "pmid": "", "doi": "10.4254/wjh.v18.i4.116153", "url": "https://doi.org/10.4254/wjh.v18.i4.116153", "status_flags": [ "none_found" ], "carries_claims": [ "C17" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "DOI:10.4254/wjh.v18.i4.116153", "access_depth": "full_text_partial", "access_note": "Publisher full text read (wjgnet.com, World J Hepatol v18 i4 article 116153): title, author list, journal, volume, issue, article number and every figure carried in C17 confirmed against the publisher record on 2026-09-27. First author confirmed as Ankit Agarwal. Not PubMed-indexed on that date, so no PMID exists to record; the record was verified at the publisher instead of by index lookup. No supplement audit claimed.", "identifier_note": "No PMID: not indexed in PubMed at time of review. DOI resolved via CrossRef 2026-09-27 — title, journal, volume, issue and year all match the citation as written. DOI-only is permitted where no PMID exists; the blank is now explained rather than bare.", "redteam_note": "No PMID: not indexed in PubMed at time of review. DOI resolved via CrossRef 2026-09-27 — title, journal, volume, issue and year all match the citation as written. DOI-only is permitted where no PMID exists; the blank is now explained rather than bare. Prose reference printed the same DOI twice; corrected. Publisher full text re-read 2026-09-27 and every figure in C17 re-checked digit for digit." }, { "n": 18, "citation": "Bruggeman A et al. Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate Parkinson's disease (GUT-PARFECT): a double-blind, placebo-controlled, randomised, phase 2 trial. EClinicalMedicine. 2024;71:102563.", "tier": "A", "kind": "rct", "pmid": "38686220", "doi": "10.1016/j.eclinm.2024.102563", "url": "https://pubmed.ncbi.nlm.nih.gov/38686220/", "status_flags": [ "none_found" ], "carries_claims": [ "C18" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "NCT03808389", "access_depth": "full_text_complete", "access_note": "PMC11056595 full text read end to end, including the secondary-outcome paragraph and the discussion of the placebo response.", "redteam_note": "Row previously gave the trial acronym in place of the author and declared abstract depth while claim C18 rested on a full-text clause. Author restored and depth corrected after reading the full text." }, { "n": 19, "citation": "Scheperjans F et al. Fecal Microbiota Transplantation for Treatment of Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2024;81(9):925–938.", "tier": "A", "kind": "rct", "pmid": "39073834", "doi": "10.1001/jamaneurol.2024.2305", "url": "https://pubmed.ncbi.nlm.nih.gov/39073834/", "status_flags": [ "none_found" ], "carries_claims": [ "C19" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "NCT04854291", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted.", "redteam_note": "Post-verification: citation title was shortened or paraphrased; replaced with the exact PubMed title, re-verified 2026-09-27." }, { "n": 20, "citation": "Wang J et al. Colonoscopic fecal microbiota transplantation for Mild-to-Moderate Parkinson's Disease: A randomized controlled trial. Brain Behav Immun. 2025;130:106086.", "tier": "A", "kind": "rct", "pmid": "40848995", "doi": "10.1016/j.bbi.2025.106086", "url": "https://pubmed.ncbi.nlm.nih.gov/40848995/", "status_flags": [ "none_found" ], "carries_claims": [ "C20" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:40848995", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted.", "redteam_note": "Post-verification: citation title was shortened or paraphrased; replaced with the exact PubMed title, re-verified 2026-09-27. The word “Fresh” appeared in the cited title and is not in the published one; removed." }, { "n": 21, "citation": "Zhang R et al. Gut microbiota modulation via repeated donor fecal transplantation improves motor and gastrointestinal symptoms in drug-naïve Parkinson's disease: a randomized phase 2 trial. Signal Transduct Target Ther. 2026;11(1):94.", "tier": "A", "kind": "rct", "pmid": "41826284", "doi": "10.1038/s41392-026-02604-9", "url": "https://pubmed.ncbi.nlm.nih.gov/41826284/", "status_flags": [ "none_found" ], "carries_claims": [ "C21" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "ChiCTR2200064151", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted.", "redteam_note": "Post-verification: citation title was shortened or paraphrased; replaced with the exact PubMed title, re-verified 2026-09-27." }, { "n": 22, "citation": "Figura M et al. Safety and Efficacy of Fecal Microbiota Transplantation in Alleviating Symptoms of Parkinson's Disease: A Randomized, Placebo-Controlled, Double-Blinded Study. Ann Neurol. 2026;100(1):10–21.", "tier": "A", "kind": "rct", "pmid": "41674471", "doi": "10.1002/ana.78153", "url": "https://pubmed.ncbi.nlm.nih.gov/41674471/", "status_flags": [ "none_found" ], "carries_claims": [ "C22" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "NCT05204641", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted.", "redteam_note": "Post-verification: citation title was shortened or paraphrased; replaced with the exact PubMed title, re-verified 2026-09-27." }, { "n": 23, "citation": "Fretheim H et al. Faecal microbiota transplantation in patients with systemic sclerosis and lower gastrointestinal tract symptoms in Norway (ReSScue): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Rheumatol. 2025;7(5):e323–e332.", "tier": "A", "kind": "rct", "pmid": "39900089", "doi": "10.1016/S2665-9913(24)00334-5", "url": "https://pubmed.ncbi.nlm.nih.gov/39900089/", "status_flags": [ "none_found" ], "carries_claims": [ "C23" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "NCT04300426", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted.", "redteam_note": "Prior pass filled the DOI. This pass found the row still carried no journal, volume or pages; the full citation was resolved in PubMed on 2026-09-27 and written in." }, { "n": 24, "citation": "Forslund K et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015;528(7581):262–266.", "tier": "A", "kind": "primary", "pmid": "26633628", "doi": "10.1038/nature15766", "url": "https://pubmed.ncbi.nlm.nih.gov/26633628/", "status_flags": [ "none_found" ], "carries_claims": [ "C24" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:26633628", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted.", "redteam_note": "Post-verification: citation title was shortened or paraphrased; replaced with the exact PubMed title, re-verified 2026-09-27." }, { "n": 25, "citation": "Vandeputte D et al. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut. 2016;65(1):57–62.", "tier": "A", "kind": "primary", "pmid": "26069274", "doi": "10.1136/gutjnl-2015-309618", "url": "https://pubmed.ncbi.nlm.nih.gov/26069274/", "status_flags": [ "none_found" ], "carries_claims": [ "C25" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:26069274", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted." }, { "n": 26, "citation": "Falony G et al. Population-level analysis of gut microbiome variation. Science. 2016;352:560–564.", "tier": "A", "kind": "primary", "pmid": "27126039", "doi": "10.1126/science.aad3503", "url": "https://pubmed.ncbi.nlm.nih.gov/27126039/", "status_flags": [ "none_found" ], "carries_claims": [ "C26" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:27126039", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted." }, { "n": 27, "citation": "Wu H et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017;23(7):850–858.", "tier": "A", "kind": "rct", "pmid": "28530702", "doi": "10.1038/nm.4345", "url": "https://pubmed.ncbi.nlm.nih.gov/28530702/", "status_flags": [ "none_found" ], "carries_claims": [ "C27" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:28530702", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted.", "redteam_note": "Post-verification: citation title was shortened or paraphrased; replaced with the exact PubMed title, re-verified 2026-09-27." }, { "n": 28, "citation": "Sampson TR et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell. 2016;167(6):1469–1480.e12.", "tier": "A", "kind": "primary", "pmid": "27912057", "doi": "10.1016/j.cell.2016.11.018", "url": "https://pubmed.ncbi.nlm.nih.gov/27912057/", "status_flags": [ "none_found" ], "carries_claims": [ "C28" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:27912057", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted.", "redteam_note": "Added from revision B. Supplies the third independent rodent line for SC2 - depletion, recolonization and metabolite substitution - which grading A did not carry." }, { "n": 29, "citation": "Neyrinck AM et al. Fecal transplantation from humans with obesity to mice drives a selective microbial signature without impacting behavioral and metabolic health. Sci Rep. 2025;15(1):15455.", "tier": "A", "kind": "primary", "pmid": "40316655", "doi": "10.1038/s41598-025-99047-z", "url": "https://pubmed.ncbi.nlm.nih.gov/40316655/", "status_flags": [ "none_found" ], "carries_claims": [ "C29" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:40316655", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted.", "redteam_note": "Added from revision B. A failed transfer; grading A's rodent evidence contained none." }, { "n": 30, "citation": "Daoust L et al. Gnotobiotic mice housing conditions critically influence the phenotype associated with transfer of faecal microbiota in a context of obesity. Gut. 2023;72(5):896–905.", "tier": "A", "kind": "primary", "pmid": "36881441", "doi": "10.1136/gutjnl-2021-326475", "url": "https://pubmed.ncbi.nlm.nih.gov/36881441/", "status_flags": [ "none_found" ], "carries_claims": [ "C30" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:36881441", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted.", "redteam_note": "Added from revision B. The housing reversal is the named reason Η is refused for SC2." }, { "n": 31, "citation": "Vrieze A et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143(4):913–916.e7.", "tier": "A", "kind": "rct", "pmid": "22728514", "doi": "10.1053/j.gastro.2012.06.031", "url": "https://pubmed.ncbi.nlm.nih.gov/22728514/", "status_flags": [ "none_found" ], "carries_claims": [ "C31" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:22728514", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted.", "redteam_note": "Added from revision B. The founding positive human metabolic transfer result, absent from grading A's ledger." }, { "n": 32, "citation": "David LA et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505(7484):559–563.", "tier": "A", "kind": "primary", "pmid": "24336217", "doi": "10.1038/nature12820", "url": "https://pubmed.ncbi.nlm.nih.gov/24336217/", "status_flags": [ "none_found" ], "carries_claims": [ "C32" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:24336217", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted.", "redteam_note": "Added from revision B. An interventional, not observational, demonstration that human composition is downstream of diet - the strongest single record against SC5's direction." }, { "n": 33, "citation": "Roager HM et al. Colonic transit time is related to bacterial metabolism and mucosal turnover in the gut. Nat Microbiol. 2016;1(9):16093.", "tier": "A", "kind": "primary", "pmid": "27562254", "doi": "10.1038/nmicrobiol.2016.93", "url": "https://pubmed.ncbi.nlm.nih.gov/27562254/", "status_flags": [ "none_found" ], "carries_claims": [ "C33" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:27562254", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted.", "redteam_note": "Added from revision B." }, { "n": 34, "citation": "Prosty C et al. Causal role of the gut microbiome in certain human diseases: a narrative review. eGastroenterology. 2024;2(3):e100086.", "tier": "B", "kind": "review", "pmid": "39944364", "doi": "10.1136/egastro-2024-100086", "url": "https://pubmed.ncbi.nlm.nih.gov/39944364/", "status_flags": [ "none_found" ], "carries_claims": [ "C34" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:39944364", "access_depth": "full_text_partial", "access_note": "Publisher full text read through the conclusions on causality and on obesity trials; no supplement audit claimed.", "redteam_note": "Added from revision B, which cited it as eGastroenterology 2025; the record is 2024. Year corrected. Field framing only: Tier B may not carry a number. Post-verification: the record is PubMed-indexed as PMID 39944364 (PMC11770457, entered 2024-09-10); PMID and PubMed url added, year 2024 re-confirmed." }, { "n": 35, "citation": "Metwaly A, Kriaa A, Hassani Z, et al. (Human Microbiome Action Consortium). A Consensus Statement on establishing causality, therapeutic applications and the use of preclinical models in microbiome research. Nat Rev Gastroenterol Hepatol. 2025;22(5):343–356.", "tier": "B", "kind": "consensus_statement", "pmid": "40033063", "doi": "10.1038/s41575-025-01041-3", "url": "https://pubmed.ncbi.nlm.nih.gov/40033063/", "status_flags": [ "none_found" ], "carries_claims": [ "C35" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:40033063", "access_depth": "full_text_partial", "access_note": "Publisher full text read through the Findings and the Delphi consensus-on-causality section; no supplement audit claimed.", "redteam_note": "Added from revision B, whose row carried no author, journal, volume or PMID - an invented short title beside a DOI, which passed validator 2.4 because a DOI is present. Full record resolved and written in. This is the Divergence basis; Tier B may not carry a number, so its consensus percentages are deliberately not registered as figures." }, { "n": 36, "citation": "Sanna S et al. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nat Genet. 2019;51(4):600–605.", "tier": "A", "kind": "primary", "pmid": "30778224", "doi": "10.1038/s41588-019-0350-x", "url": "https://pubmed.ncbi.nlm.nih.gov/30778224/", "status_flags": [ "none_found" ], "carries_claims": [ "C36" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:30778224", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted. The butyrate p-value is truncated in the retrieved record and is therefore not carried as a figure.", "redteam_note": "Omission-audit addition, in neither input. Overturns grading A's upper-ladder claim that no Mendelian-randomization instrument was identified." }, { "n": 37, "citation": "Koeth RA et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19(5):576–585.", "tier": "A", "kind": "primary", "pmid": "23563705", "doi": "10.1038/nm.3145", "url": "https://pubmed.ncbi.nlm.nih.gov/23563705/", "status_flags": [ "none_found" ], "carries_claims": [ "C37" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:23563705", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted.", "redteam_note": "Omission-audit addition, in neither input. Overturns grading A's upper-ladder claim that no human withdrawal/rechallenge experiment was identified, and is the clearest worked example of caps 2 and 4 binding a case that looks convergent." }, { "n": 38, "citation": "Bajaj JS et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology. 2017;66(6):1727–1738.", "tier": "A", "kind": "rct", "pmid": "28586116", "doi": "10.1002/hep.29306", "url": "https://pubmed.ncbi.nlm.nih.gov/28586116/", "status_flags": [ "none_found" ], "carries_claims": [ "C38" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:28586116", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted.", "redteam_note": "Omission-audit addition, in neither input. The earlier randomized hepatic-encephalopathy result that the 2025 phase II trial builds on; tests SC4 upward." }, { "n": 39, "citation": "Davar D et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021;371(6529):595–602.", "tier": "A", "kind": "clinical_trial", "pmid": "33542131", "doi": "10.1126/science.abf3363", "url": "https://pubmed.ncbi.nlm.nih.gov/33542131/", "status_flags": [ "none_found" ], "carries_claims": [ "C39" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "PMID:33542131", "access_depth": "abstract_metadata", "access_note": "PubMed record and abstract read; full article not asserted.", "redteam_note": "Omission-audit addition, in neither input. A positive human distant-organ (tumour) signal, included so the omission audit is not one-directional; single-arm, so it is a record and not a controlled perturbation." } ], "independence_basis": { "required": true, "lines": [ { "label": "Single-species add-back into a germ-free susceptible host (SFB, arthritis)", "sources": [ 1 ], "serves_subclaim": "SC2", "excludes_error": "Cannot be a donor-variability, whole-community or diet-composition artefact: one defined organism was introduced into an otherwise sterile host and the phenotype followed." }, { "label": "Removal of a resident microbial function with metabolite add-back in conventionally raised mice (deoxycholic acid, hepatocellular carcinoma)", "sources": [ 5 ], "serves_subclaim": "SC2", "excludes_error": "Immune to both the germ-free-artefact and the forced-transfer failure modes, because the animals were never gnotobiotic and nothing was transferred into them." }, { "label": "Depletion, recolonization and metabolite substitution in an alpha-synuclein model (short-chain fatty acids, motor and microglial phenotypes)", "sources": [ 28 ], "serves_subclaim": "SC2", "excludes_error": "A different mediator class and a different organ system, so it cannot share a failure mode with an immune-mediated arthritis result or with a bile-acid genotoxicity result." }, { "label": "Human-donor whole-community transfer into germ-free recipients with cohousing rescue", "sources": [ 2 ], "serves_subclaim": "SC2", "excludes_error": "Excludes the objection that only laboratory-derived organisms move phenotypes. The weakest of the four: its effect is diet-dependent by the study's own report, and sources 29 and 30 show the same paradigm failing or reversing under other diets and housing." }, { "label": "Human recurrent-CDI whole-stool restoration", "sources": [ 14 ], "serves_subclaim": "SC3", "excludes_error": "Randomized against antibiotic comparators, so the effect cannot be the antibiotic course itself." }, { "label": "Human recurrent-CDI purified-spore therapy", "sources": [ 15 ], "serves_subclaim": "SC3", "excludes_error": "Placebo-controlled with a defined purified product, so no single procedure-specific bias of whole-stool infusion explains both CDI lines." } ], "shared_failure_mode_checked": true, "note": "Four lines carry SC2 (Ζ) and two carry SC3 (Ε). The four rodent lines share only the species; they differ in organism, mediator, organ, modality and whether the host was ever germ-free, so no single systematic error produces all four. The two CDI lines share the post-antibiotic depleted niche, which is why SC3 is Ε and not Ζ. **Neither group carries SC5**, the graded claim, which has no independent causal line at all - and that, not any cap, is the reason the aggregate is Γ.", "redteam_note": "Grading A named three rodent lines and two CDI lines. This pass added the alpha-synuclein depletion/add-back line, labelled every line with the subclaim it serves, and marked the human-donor transfer line as the weakest after admitting the failed-transfer and housing-reversal records that revision B supplied. Revision B recorded no independence basis at all, having scored every subclaim below Ζ." }, "thresholds_tested": [ { "subclaim_id": "SC1", "threshold": "Δ", "requirement_quoted": "Requires a transfer paradigm or causal perturbation in vivo.", "satisfied": "no", "supporting_evidence": [ "[24]–[27] describe disease signatures, medication, and transit; they do not perturb a prespecified disease-associated signature and show phenotype movement." ], "what_would_cross_it": "A prespecified human disease-associated composition shift, tested by a field-valid in-vivo perturbation or equivalent, changes an extraintestinal phenotype." }, { "subclaim_id": "SC2", "threshold": "Η", "requirement_quoted": "Requires a defined consortium or factor rescue in multiple contexts, a narrowed mechanism, and strong exclusion of diet, housing, batch, and handling confounds.", "satisfied": "no", "supporting_evidence": [ "[1], [5], [28] and [2] supply four perturbation lines with defined strain or defined microbial function and add-back, removal or rescue logic, across arthritis, hepatic, motor and metabolic phenotypes - satisfying all three Ζ bullets inside the rodent scope.", "Η fails on its own quoted requirement: no narrowed mechanism is replicated across models, and 'strong exclusion of diet, housing, batch, and handling confounds' is contradicted by [29], [30] and [7]." ], "what_would_cross_it": "Replicate a narrowed strain/function mechanism with rescue in multiple independently housed models while controlling diet, genotype, batch, and handling." }, { "subclaim_id": "SC3", "threshold": "Ζ", "requirement_quoted": "Requires defined consortium or strain-level causal evidence, rescue logic, and replication across at least two relevant models or cohorts.", "satisfied": "no", "supporting_evidence": [ "[14] and [15] show replicated recurrence reduction after microbial restoration, but whole-stool FMT and donor-derived spore product do not isolate strain-level identity with rescue logic." ], "what_would_cross_it": "Show which defined strains or consortium restore colonization resistance and reproduce the effect with add-back/removal logic in independent relevant cohorts." }, { "subclaim_id": "SC4", "threshold": "Ζ", "requirement_quoted": "Requires defined consortium or strain-level causal evidence, rescue logic, and replication across at least two relevant models or cohorts.", "satisfied": "no", "supporting_evidence": [ "[8]-[13], [16]-[23], [31], [38] and [39] include positive, null and transient treatment signals, and [36] adds a human genetic instrument, but most interventions use crude or incompletely defined communities and none resolves strain-level identity with rescue logic.", "Ε is satisfied rather than Δ because the limits are mapped by internal negative controls inside the positive trials, not merely untested - see generalization_check." ], "what_would_cross_it": "Replicate a prespecified strain/consortium intervention with target engagement, rescue logic, and durable organ-specific outcomes in independent cohorts." }, { "subclaim_id": "SC5", "threshold": "Δ", "requirement_quoted": "Requires a transfer paradigm or causal perturbation in vivo; the threshold must be crossed within the scope being scored.", "satisfied": "no", "supporting_evidence": [ "Animal transfers and human post-diagnosis microbiota therapies move selected phenotypes in their own scopes [1]-[23], [28]-[31], [38]-[39]; none shows that a defined community shift initiates or is a primary cause of incident human disease across distant organs.", "The two field-valid equivalents that reach human biology stop short: [36] instruments one microbial function against one trait class in one cohort, and [37]'s human endpoint is a metabolite, which universal cap 4 holds at Γ.", "[32] and [33] run the other way: diet change reconfigures the human community experimentally, and transit tracks it, so the composition offered as the cause is demonstrably also an effect." ], "what_would_cross_it": "A relevant pre-onset, defined human community perturbation or credible field-valid equivalent must alter a prespecified incident/progressive distant-organ disease endpoint." } ], "redteam_review": { "performed": true, "date": "2026-09-27", "pass": "pass-01-2026-09-27 (full synthesis of two input versions)", "reviewer": "Claude (Anthropic) - independent model, different model family from the graders", "independent_verification": { "ledger_rows_resolved": 42, "rows_in_final_ledger": 39, "records_checked_against_PubMed": 40, "records_resolved_at_publisher": 2, "claims_checked": 36, "claims_verified": 36, "claims_contradicted": 0, "full_text_read": [ "GUT-PARFECT (PMC11056595)", "Agarwal 2026 (publisher)", "Prosty 2024 (publisher)", "Metwaly 2025 (publisher)" ], "method": "Every ledger row of both inputs resolved and compared on title, first author, journal, year, volume, pages and DOI; DOI checked to belong to the same paper; retraction status checked on every record; every registered claim checked against the source, numbers digit for digit." }, "findings_summary": [ "RT-01 major: grading A's upper-ladder check denied a Mendelian-randomization instrument that exists (Sanna 2019). Fixed; the equivalent is now assessed rather than denied.", "RT-02 major: grading A's upper-ladder check denied a human withdrawal/rechallenge experiment that exists (Koeth 2013). Fixed; cap 4 is now the named reason it does not carry the claim.", "RT-03 major: revision B's stated reason for two downgrades, 'the v5.4 specificity and generalization thresholds', is not a rule in v5.4 or in any rubric. Rejected.", "RT-04 major: revision B lowered SC2 to Ε by applying Η's 'narrowed mechanism' requirement at Ζ. Rejected; Ζ held on four lines that pass the shared-failure test.", "RT-05 major: revision B lowered the human-treatment subclaim to Δ by inverting pitfall 16, after removing five of the six trials that map the boundary. Rejected; Ε held.", "RT-06 major: Divergence recomputed. A used the claim's wording, which the framework forbids; B used field framing but for the wrong claim and misread both cited sources. Implied level Ζ, gap +3, severe overstatement.", "RT-07 major: revision B dropped 20 of grading A's 27 records, including the whole recurrent-CDI base, without stating why. Union ledger restored.", "RT-08 major, in revision B's favour: rodent transferability is less robust than grading A's ledger showed. B's failed-transfer and housing-reversal records adopted; they are the named reason Η is refused for SC2.", "RT-09 major (scope): recurrent CDI is out of scope for a distant-organ claim and is labelled so rather than deleted, per the index's own adjudication note.", "RT-10 minor: decomposition adjudicated between two overlapping index entries; A's five subclaims retained as a superset of both prescriptions.", "RT-11 minor: causal tally recounted against the union ledger - 28 records, 18 favourable, 8 null, 2 context-dependent.", "RT-12 minor: documentation defects in both inputs fixed (duplicated derivation clause, broken prose table header, duplicated DOI, two unreconstructable citations, two under-identified rows).", "RT-13 major (blocking): no lay summary in grading A - its only validator 2.4 failure. Revision B's lay summary adopted as the base and extended.", "RT-14 minor: role of mechanism re-derived from step 1 rather than inherited; held at reinforcing / stabilizing factor, with permissive factor recorded for the CDI scope.", "RT-15: symmetric-scepticism record. Two downgrades in the newer input rejected, Divergence moved up rather than down, two absence claims overturned by evidence running for the hypothesis, Δ for SC5 seriously entertained and rejected on three named blockers. Net effect on the letter: none.", "RT-16: HPylori.zip in the owner's input folder is byte-identical to the B package (md5 8c02128ae77d07a0570bcedfe1738b94) and contains no H. pylori material; the posted H. pylori review was not touched." ], "level_unchanged": true, "subclaim_levels_changed_vs_A": 0, "subclaim_levels_changed_vs_B": 3, "identifier_defects": { "critical": 0, "major": 5, "minor": 6 }, "claim_defects": { "critical": 0, "contradicted": 0, "major": 1, "minor": 1 }, "residual_limitations": [ "Two gradings by the same model family, plus one independent red-team synthesis. Not three independent gradings.", "Not a calibration entry; no blinded run.", "Twenty-seven of thirty-nine rows were read at abstract depth. Every figure carried in the review was checked against the record, but no supplement audit is claimed.", "The Delphi consensus that fixes the Divergence implied level is one instrument; a different reading of field framing would move the gap, though not below +2 on any reading of the sources found." ], "prior_pass": { "performed": true, "date": "2026-09-27", "reviewer": "Claude (Anthropic) — independent model, adversarial pass", "independent_verification": { "records_checked_against_PubMed": 5, "records_exact": 5, "records_resolved_via_CrossRef": 1, "method": "Ledger entries retrieved and compared on title, journal, volume, pages, DOI." }, "findings": [ "Two ledger rows carried empty DOI fields where DOIs exist (13, 23). Filled.", "Row 17 carried no PMID with no explanation; paper is real but not PubMed-indexed. Resolved via CrossRef and the blank is now explained.", "The independence basis mixed lines serving SC2 with lines serving SC3 without labels. Labelled.", "Role value describes the graded scope only; SC3's context has a different role. Noted.", "Step 0 was handled correctly: the index wording was a conjunction, typed as such and restated. No correction needed.", "Negative trials (C13, C17, C23) are admitted and scored as negative evidence rather than omitted. No correction needed.", "SC3's scope explicitly records that CDI evidence is local, not distant-organ, and the independence note already stated that neither line group carries SC5. Both pre-empt the objections a redteam would otherwise raise." ], "level_unchanged": true, "residual_limitations": [ "Single grading; no independent second grading of this hypothesis.", "Not a calibration entry; no blinded run." ] } }, "consensus_validation": { "slug": "gut-microbiome-systemic-causality", "completed": true, "provider_mode": "Consensus MCP keyword search and paper-record fetch; independent comparison with primary PubMed records and existing topic inventories", "queries": [ "gut microbiota causal systemic disease human randomized fecal microbiota transplantation autoimmune arthritis type 2 diabetes cardiovascular disease mechanisms primary studies", "primary human randomized fecal microbiota transplantation trial Kootte 2017 Vrieze 2012 Yu FMT-TRIM autoimmune arthritis segmented filamentous bacteria Wu 2010" ], "raw_paths": [ "D:\\HypothesisCritic\\deliverables\\consensus_consistency_audit_2026-10-09\\checks\\gut-microbiome-systemic-causality\\consensus-search-01.json", "D:\\HypothesisCritic\\deliverables\\consensus_consistency_audit_2026-10-09\\checks\\gut-microbiome-systemic-causality\\consensus-search-02.json", "D:\\HypothesisCritic\\deliverables\\consensus_consistency_audit_2026-10-09\\checks\\gut-microbiome-systemic-causality\\consensus-fetch-c46f8701dfcf5ac1911e15b130428f46.json", "D:\\HypothesisCritic\\deliverables\\consensus_consistency_audit_2026-10-09\\checks\\gut-microbiome-systemic-causality\\consensus-fetch-9df9e85d89ea5addbfae4573b28db55c.json" ], "primary_comparisons": [ { "pmid": "20620945", "depth": "PubMed abstract_metadata in baseline inventory", "result": "Segmented filamentous bacteria drive Th17-associated autoimmune arthritis in a mouse model; bounded animal causality, not broad human systemic primacy.", "loadbearing_claim_ids": [ "C1" ] }, { "pmid": "24009397", "depth": "PubMed abstract, reopened 2026-10-09", "result": "Fecal microbiota from obesity-discordant twins transferred body/fat-mass and metabolic phenotypes to germ-free mice; diet-dependent and animal transfer.", "loadbearing_claim_ids": [ "C2" ] }, { "pmid": "32150549", "depth": "PubMed abstract_metadata in baseline inventory", "result": "FMT-TRIM placebo-controlled pilot in obesity did not improve the primary metabolic endpoint; weighs against assuming human systemic metabolic effects from transfer.", "loadbearing_claim_ids": [ "C9" ] }, { "pmid": "28978426", "depth": "PubMed abstract_metadata in baseline inventory", "result": "Lean-donor FMT effect on insulin sensitivity depended on baseline microbiota and was short-term; not disease initiation or general systemic cause.", "loadbearing_claim_ids": [ "C8" ] } ], "grade_changed": false, "conclusion": "No grade change: Γ for microbial composition as a broad primary cause across distant human organ diseases. Historical mention is field-level Delphi consensus, not Consensus service provenance; fresh searches are retrospective only.", "addendum_path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\gut-microbiome-systemic-causality\\consensus-addendum.md", "additional_original_source_receipts": [ "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\gut-microbiome-systemic-causality\\primary-source-verification.json", "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\gut-microbiome-systemic-causality\\primary-source-verification.md", "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\gut-microbiome-systemic-causality\\source-verification.json", "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\gut-microbiome-systemic-causality\\source-verification.md" ], "primary_comparison_count": 4, "status": "completed_retrospective_original_source_reconciliation", "score_before": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Moderate", "confidence_rationale": "Multiple causal animal lines, strong human CDI trials, and emerging but conflicting human systemic interventions support the narrow mechanisms; broad human primacy is not directly tested.", "rests_on_non_peer_reviewed_work": false, "rationale": "Gut communities can causally modify selected animal phenotypes and recurrent CDI, with mixed context-specific human metabolic, hepatic, and Parkinson signals. No evidence establishes community composition as a primary cause across human distant-organ disease classes." }, "score_after": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Moderate", "confidence_rationale": "Multiple causal animal lines, strong human CDI trials, and emerging but conflicting human systemic interventions support the narrow mechanisms; broad human primacy is not directly tested.", "rests_on_non_peer_reviewed_work": false, "rationale": "Gut communities can causally modify selected animal phenotypes and recurrent CDI, with mixed context-specific human metabolic, hepatic, and Parkinson signals. No evidence establishes community composition as a primary cause across human distant-organ disease classes." }, "raw_receipts": [ { "path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\gut-microbiome-systemic-causality\\consensus-search-01.json", "sha256": "9f9815adbe5a08dd264ffc09ce16ec9d990a370f905e07838331e047b94144c1" }, { "path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\gut-microbiome-systemic-causality\\consensus-search-02.json", "sha256": "dae7c0b04695c00620ce74d5dd5eeb91e78b1354efb13dfe6727a3f067805b59" }, { "path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\gut-microbiome-systemic-causality\\consensus-fetch-c46f8701dfcf5ac1911e15b130428f46.json", "sha256": "3c8032cdc215e77ff3f93f5c1c75ecc6c04907d888109941c4900cd1b50b3e67" }, { "path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\gut-microbiome-systemic-causality\\consensus-fetch-9df9e85d89ea5addbfae4573b28db55c.json", "sha256": "198a234d3e32acec5936d483b0a294eeb21efe633cdfe0e0b21e7cebd96c3c19" }, { "path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\gut-microbiome-systemic-causality\\primary-source-verification.json", "sha256": "b1fea0e7cd3bb63f86b84b54e99766aa75e35a946ef1f9fa11e7ed9e30889449" }, { "path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\gut-microbiome-systemic-causality\\primary-source-verification.md", "sha256": "ea6de20544b5d1c4ba8a43b31c53997b2632c481b36e9306cd2a8da20507f066" }, { "path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\gut-microbiome-systemic-causality\\source-verification.json", "sha256": "11422bef9f0bd722bc15baed509f2ab3d48e90802678265c52b883d1a1c650d7" }, { "path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\gut-microbiome-systemic-causality\\source-verification.md", "sha256": "353f5a35d6498ace026ca2c5f99a420b0541586883c31c325100216f696d9e1e" } ], "manifest_source": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\gut-microbiome-systemic-causality\\consensus-validation.json", "literature_cutoff_preserved": true, "independent_blinded_audit": false } }